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ABSTRACT

The roles of dietary polyphenols, such as resveratrol found in red wine and grape seed
extract, have become an increasingly more popular research topic. Dietary polyphenols
have even achieved media success for their potential benefits on human health and
disease. The success is frequently attributed to the compounds’ antioxidant and reactive
oxygen species (ROS) scavenging abilities. Not only are polyphenols highlighted as the
benefitial health constituents of herbal remedies, but there are also two plant-polyphenol
drugs approved by the United States Food and Drug Administration, Crofelemer (a
proanthocyanidin oligomer from Croton lechleri) and Veregen (catechins from
Camellia sinensis). Due to the demand for novel polyphenolic lead compounds, three
major classes were chosen to be explored as part of this dissertation: stilbenes,
gallotannins, and ellagitannins. The investigation of stilbenes includes an invited
literature update on novel natural stilbenes, which have been isolated and identified
since 2009. The review concludes by discussing the biological activities and potential
health benefits of this polyphenol sub-class. Additionally, two new monomeric
stilbenes, namely, vulpinoideols A and B, along with ten known compounds were
isolated from a fox sedge (Carex vulpinoidea) acetone seed extract. All of the isolates
were evaluated for their tyrosinase enzyme inhibitory activity, along with the wellknown competitive inhibitor, arbutin. A synthetic route for naturally isolated
gallotannins, namely, maplexins F and J, previously isolated from red maple (Acer
rubrum) tree bark, was developed. Additionally, the ligand-enzyme interaction between
the gallotannins and their target enzyme, α-glucosidase, was evaluated using
ii

biophsyical tools including isothermal titration calorimetry (ITC), fluorescence, and
circular dichroism (CD) spectroscopic methods. Finally, a synthetic route was also
developed for the ellagitannin gut-microbial metabolites, urolithins (dibenzopyranone
derivatives), along with analytical UFLC-MS/MS methods to study the cellular and
tissue uptake of the urolithins, as well as other dietary polyphenolic metabolites of
interest.
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PREFACE

This dissertation has been written in manuscript style format.
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STATEMENT OF THE PROBLEMS
Natural products continue to provide an inspiration for new drug targets and synthetic
scaffolds.

Between 1940 and 2010, a total of 175 small-molecule, anti-cancer

therapeutics have been approved by the Food and Drug Administration. Of those 175
approved therapies, 49% were either discovered or derived directly from a natural
product [1]. Even with natural products providing such a large influence towards the
generation of new pharmaceuticals, there is still a growing demand for the discovery
of new lead compounds. This demand puts continuous pressure on finding novel
compounds, and sources, for drug candidates.

The polyphenols of interest are secondary metabolites, and are not directly responsible
for the growth and development of the producing organism.

As a result, these

compounds are frequently isolated in low yields from their natural sources. Obtaining
the natural biomass can be economically and scientifically impractical (e.g. deep ocean
bacteria or the bark of a tree). Therefore, to investigate a natural product isolate as a
potential drug candidate, a synthetic route must often be developed.

Over the past decade, the fate of dietary polyphenols upon ingestion has continued to
attract increased research attention. Several sub-classes of polyphenols are poorly
bioavailable in their intact forms, but are extensively metabolized by gut-microflora.
This results in the hydrolysis of sugar substituents, alkylation of vulnerable oxygen and
nitrogen functional groups, and a series of oxidation-reduction reactions. The final
metabolite of dietary polyphenols often has a completely different chemical structure

1

and set of properties from what was originally consumed. As these metabolized
polyphenols are, in fact, the biologically available metabolic endproducts, it is
imperative to develop analytical methods for evaluating the potential impact of these
compounds.

[1]

G. M. Cragg and D. J. J. Nat. Prod. 2012, 60, 52-60.
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CHAPTER 1
STILBENES

Manuscript 1 appears as published:
Invited Review: Beyond Resveratrol: A Review of Natural Stilbenoids Identified from
2009-2013. Niesen, Daniel B.; Hessler, Craig; Seeram, Navindra P. (2013) Journal of
Berry Research. 4, 181-196…………………………………………………….……..8

Manuscript 2 appears as published:
Phenolic Constituents of Carex vulpinoidea Seeds and their Tyrosinase Inhibitory
Activities. Niesen, Daniel B.; Ma, Hang; Yuan, Tao; Bach, Alvin C. II; Henry, Geneive
E.; Seeram, Navindra P. (2015). Natural Product Communications. 10, 491-493…..38
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ABSTRACT
Natural stilbenes have become an increasingly popular research topic of many natural
product groups throughout the world, due to their elaborate structures and dynamic
biological activities. Stilbenes are phenolic compounds, and are an exciting class that
have been found in 33 plant families. Even though their carbon monomeric form is a
simple 1,2-diphenylethylene unit, stilbenes display a wide variety of polymerization
and oligomer construction [1]. They most commonly refer to the compounds that are
hydroxylated derivatives of the stilbene carbon backbone. Stilbenes have been isolated
in monomeric forms, like resveratrol, oligomer forms, such as α-viniferin, and
glycosides like astringin [1].

Stilbenes are produced as a woody metabolite, and may serve as constitutive and
inductive defense agents. The antimicrobial activity of plant stilbenes, and the fact that
they are both constitutive and inducible, strongly suggests that their concentrations are
a good indication of their role in disease resistance [1]. Because of this, stilbenes have
been the focus of a variety of research topics for their potential benefits.

Resveratrol has been extensively studied due to its wide range of biological activities
and occurrence in plant foods, including grape and some berries. Apart from the intact
resveratrol molecule and closely related analogs, this compound can be regarded as a
monomer which occurs as a primary building block for subsequent polymerization,
which leads to the extensive structural diversity within the chemical classification.

4

Stilbenoids exhibit a vast array of polymerization and oligomeric construction, with
over 60 such naturally occurring stilbenes being isolated and identiﬁed in the last ﬁve
years alone, adding to the hundreds which are already known to date (Manuscript 1).

The Carex genus (family, Cyperaceae) contains over 2000 species [2], but the majority
of these remain largely uninvestigated for their phytochemical constituents. This is
unfortunate, considering that the Cyperaceae family is one of the few plant families
known to produce stilbenoid derivatives [3, 4]. Previously, our group has studied Carex
species found in the northern regions of the United States, which has yielded several
bioactive phenolic constituents, including resveratrol oligomers and other stilbenoids
[5, 6].

Hyperpigmentary disorders, such as melasma and freckles, are due to the abnormal
accumulation of melanin. The tyrosinase enzyme has been implicated as a key enzyme
in melanogenesis, as it initiates an enzymatic cascade through the conversion of
tyrosine and 3, 4-dihydroxyphenylalanine (L-DOPA) into DOPA-quinone [7, 8].
Notably, plant natural products, in particular, phenolic compounds, have shown great
promise as tyrosinase inhibitors, a primary example being the phenolic glycoside,
arbutin, which is widely used for commercial cosmetic applications [9, 10]. Moreover,
several phenolic sub-classes, including flavonoids, chalcones, and stilbenoids, are
known to be tyrosinase inhibitors [11-13].

5

In the pursuit to of novel stilbenoids, the seeds of the previously uninvestigated Carex
vulpinoidea Michx were investigated for their phytochemical composition.

The

isolates were also evaluated for their anti-tyrosinase activities. The approach involved
isolation

and

structural

elucidation

of

phytochemicals

by using

various

chromatographic separation techniques and analytical approaches including NMR
(nuclear magnetic resonance) spectroscopy and MS (mass spectrometry).
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Abstract
Polyphenols constitute a large chemical class of phytochemicals among which the
stilbenoid sub-class has attracted signiﬁcant attention due to their elaborate structural
diversity and biological activities.

Resveratrol, a well-known stilbene, has been

extensively studied due to its wide range of biological activities and occurrence in plant
foods, including grape and some berries. Apart from the intact resveratrol molecule and
closely related analogs, this compound can be regarded as a monomer which occurs as
a primary building block for subsequent polymerization which leads to extensive
structural diversity. Consequently, stilbenoids exhibit a vast array of polymerization
and oligomeric construction, with over 60 such naturally occurring stilbenes being
isolated and identiﬁed in the last ﬁve years alone, adding to the hundreds which are
already known to date. This review updates the literature on natural stilbenoids which
have been isolated and identiﬁed since 2009 and discusses the biological activities of
this sub-class of bioactive polyphenols as a whole.
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1.0 Introduction
1.1. Stilbenes
Over the past few decades, signiﬁcant research attention has been directed towards the
investigation of polyphenols, a large class of secondary metabolites which are abundant
in plants and plant-derived foods including grapes, and some berries and nuts. Within
the large chemical class of (poly)phenolic compounds, the stilbenoids, which occur in
33 plant families, have been extensively studied both as pure compounds and enriched
plant derived extracts [1, 2]. Consequently, their potential applications either as
botanical supplements or as active constituents in medicinal and cosmetic preparations
have been evaluated [1]. Notably, stilbenoids have been isolated and studied as
monomers and oligomers, as well as glycosylated derivatives with the best known
example being resveratrol as well as others including α-viniferin, and astringin (see
Fig. 1) [2]. The carbon skeleton of stilbenes occurs as a C6–C2–C6 unit, namely, a 1,
2-diphenylethylene moiety, however, the commonly hydroxylated derivatives provide
the class with a wide variety of polymerization and oligomeric construction. Stilbenes
are produced by plants as a woody metabolite, as well as constitutive and inductive
defense agents. The antimicrobial activity of plant stilbenes, and the nature of these
compounds as being both constitutive and inducible secondary metabolites, suggests
that their in situ concentrations are a good indication of disease resistance [2].
Historically, signiﬁcant research has focused on the role of stilbenes and their activity
as anti-bacterial agents, antioxidants, anti-inﬂammatory agents, anticancer and cancer
chemopreventive agents, and more recently their role in the regulation of several human
degenerative diseases [3-9].
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1.2. Occurrence of resveratrol in berries
The occurrence of stilbenes in berries has largely been reported for the so called ‘model
stilbenoid’ compound, namely, resveratrol (Fig. 1) which was originally isolated from
the roots of Veratrum grandiﬂorum in 1940 [10]. Notably, as mentioned previously, in
nearly every case highlighted in the current review, resveratrol has been used as the
primary building block during the polymerization into larger stilbenes.

Figure 1. Stilbene derivatives highlighting the common monomer, resveratrol (left), a
trimer α-viniferin (center), and a glycosylated derivative, astringin (right).

In many grape varieties, trans-resveratrol is a phytoalexin produced to combat the
growth of fungal pathogens such as Botrytis cinerea, a necrotic fungus whose most
notable host is wine grapes [11]. Resveratrol’s presence in Vitis vinifera grapes is also
constitutive, with a natural accumulation in the skin of ripe berries. In muscadine
grapes (Vitis rotundifolia), a species native to the southeastern United States,
resveratrol has been isolated from the seeds as well as the skin [12]. The concentration
of resveratrol present in grape skins varies with the grape cultivar, its geographic origin,
11

and exposure to infections. As red wine is fermented with the skins, it contains a higher
concentration of resveratrol as compared to white wines. Depending on the grape
variety, the concentration of resveratrol in red wines ranges between 0.2–5.8mg/L, with
a direct correlation in the amount of fermentation time a wine spends in contact with
the grape skins [13].

Resveratrol has also been detected in several other berry varieties. It has been identiﬁed
in blueberry, bilberry, cowberry, red currant, cranberry and strawberries; however these
berries contained less than 10% of that present in grapes [14, 15]. The content of transresveratrol in the fresh weight of the above fruit ranges from 3–30µg/g [15].
Additionally, it has been reported that heating and cooking the berries will contribute
to the degradation of resveratrol [14].

1.3. Occurrence of resveratrol and other stilbenes in non-berry food sources
Resveratrol and polymeric stilbenes have been found in other food sources apart from
the various berry varieties. Interestingly, a source of resveratrol derivatives is peanuts
(Arachis hypogea), in particular, sprouted peanuts, where the resveratrol content rivals
that of grape skins. Depending upon peanut cultivar, the resveratrol content ranges from
2.3–4.5µg/g before sprouting and 11.7–25.7µg/g after sprouting [16]. Two new
resveratrol dimers were recently isolated from peanut seeds and are discussed later in
this review [17]. Cocoa powder, baking chocolate, and dark chocolate have also been
reported to contain small concentrations of resveratrol in normal consumed quantities
i.e. 0.35–1.85mg/kg [18].
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1.4. Previous review articles on stilbenes
To date, there are several reviews available on the pharmacological beneﬁts of
resveratrol and its analogs [19–21]. Most recently, in 2009, Shen and co-workers have
published a comprehensive examination of the novel chemistry related to stilbenes
discovered over the time period from 1995 to late 2008 [2]. Therefore, in this review,
we examine new stilbene chemistry that has been reported from 2009 to late 2013,
bridging the gap in period previously reported by Shen and co-workers [2]. During the
current period covered herein, over 60 naturally occurring stilbenes have been isolated
and identiﬁed with structures ranging from glycosylated monomers to a hexamer.
Current scientiﬁc interest in determining the biological activity of this class of
compounds will also be highlighted.

2. Stilbenes isolated and identiﬁed since 2009
2.1. Compound classiﬁcation
While more complex classiﬁcation systems for stilbenes have been proposed by
Sootheeswaran and Pasupathy [22], for the purpose of this review, the novel chemistry
isolated has been grouped into: monomers, dimers, trimers, tetramers, and hexamer
units. Additionally there was one norstilbene isolated, as well as stilbenes containing
glycoside moieties, which we have differentiated based on their carbon-carbon or
carbon-oxygen connectivity. These compounds are discussed below.
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2.2. Stilbene monomers
Only two stilbene monomer derivatives were isolated during this time period. While
the stilbene structure provides a large variety in the ways of polymerization, the
diphenylethylene unit does not have many locations for potential modiﬁcations into
novel monomers. Although the discovery of new monomers is less common, two
prenylated derivatives were successfully isolated and identiﬁed. From black skin
peanut seeds challenged with the fungal strain Rhizopus oligoporus, Liu et al. [23]
isolated the methoxy-prenylated derivative shown in Fig. 2 (compound shown on left).
Shan and co-workers [24] successfully isolated the additional monomer, cudrastilbene,
from the roots of Cudrania tricuspidata, an ethnobotanical plant used commonly in
China, Korea, and Japan for medicinal purposes. The two new compounds can be found
in figure 2.

Figure 2. 3,5,3’-trihydroxy-4’-methoxy-5’-isopentenylstilbene (left) and cudrastilbene
(right) isolated from fungal challenged black skin peanut seeds and Cudrania
tricuspidata respectively.

2.3. Stilbene dimers
During the time period of this review, a total of 17 dimeric stilbenes were reported.
Among the oligomeric stilbenes, the resveratrol monomer is most commonly used for
construction. There are many combinations of C–C and C–O bonding patterns that can
arise during the polymerization of the resveratrol units. However, the most common is
14

the formation of the benzofuran moiety. This is apparent, as it is seen in almost all of
the newly isolated stilbene dimers.

Arguably, most structurally unique of the dimers are the two phytoalexins isolated by
Sobolev et al. [17]. Interestingly, the production of these two compounds was induced
by subjecting peanut seeds (Arachis hypogaea) to fungal (Aspergillus caelatus)
infection. Isolation and puriﬁcation of the fungal challenged seed’s chemical
constituents resulted in the discovery of two new prenylated dimers of resveratrol,
arahypin 6 and 7 (Fig. 3).

Figure 3. Arahypin 6 (left) and arahypin 7 (right) isolated from peanuts (Arachis
hypogaea).

Plants of the genus Gnetum have previously been reported to be rich sources of
oligomeric stilbene derivatives [25]. Similarly, in the current time period of 2009–
2013, for this review, this was also true with the isolation and characterization of
macrostachyols C and D from the roots of Gnetum macrostachyum (Fig. 4) [25].
Interestingly, macrostachyol C does not contain a benzofuran moiety as observed in the
majority of the stilbene dimers.
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The genus Shorea had previously been reported to contain stilbenoids, although the
work done by Patcharamun and co-workers in 2011 was the ﬁrst phytochemical
investigation conducted on Shorea ruxburghii [26], a medicinal plant used in India.
This work resulted in the isolation of roxburghiol A (Fig. 5).

Figure 4. Macrostachyols C (left) and macrostachyol D (right) isolated from Gnetum
macrostachyum.

Figure 5. Roxburghiol A isolated from Shorea roxburghii.

Vaterioside A (Fig. 6), was isolated from the leaves of Vateria indica by Ito et al. [27].
Previously, studies have shown that this carbon skeleton can be produced by exposing
ε-viniferin to photo-oxidative conditions [28]. However, this is the ﬁrst chemical
isolation from natural sources. A glycosylated form of vaterioside A was additionally
isolated during this phytochemical investigation (compound is shown in Fig. 22).
16

Four new dimers were reported from the stem wood of Hopea hainanensis by Ge et al.
[29]. This group has previously isolated, and characterized, several other stilbene
oligomers from the Hopea genus. This recent work resulted in the isolation and
characterization of four new structures, each of which has notable differences (Fig.7).
Hopeahainol C is more unsaturated when compared to the other dimers of this review,
lacking a single sp3 hybridized carbon. The relatively stereochemistry of these
compounds were unambiguously determined using NOESY experiments [29].

Figure 6. Aglycone of vaterioside A isolated from Vateria indica.

Figure 7. Hopeahainols C-F (left to right, top to bottom, respectively) isolated from
Hopea hainanensis.
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Examination of the branches and twigs of the tropical plant Vatica mangachapoiby Qin
et al. [30] afforded the three new dimers shown in Fig. 8. The compounds were isolated
in a bioassay-guided fractionation targeting compounds with xanthine oxidase (XO)
and acetylcholinesterase (AChE) inhibitory effects. Interestingly, vaticahainol A shows
rearrangement from the original resveratrol unit. The structure contains a lactone
moiety, which is not seen in the other dimers discussed in this review. Vaticahainol B
contains a quinone ring, which also has not been seen in many other isolated stilbenes.
The quinone moiety is recognized by four quaternary sp2 C-atoms and two protonated
sp2 C-atoms, which suggests the presence of a cyclohexa-2,5-dienone system. The ﬁnal
structure, vaticahainol C, contains a distinctive phenanthrene moiety [30].

Figure 8. Vaticahainols A-C (left to right, respectively) isolated from Vatica
mangachapoi.
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While studying the stems of Vatica albiramis, Abe et al. [31] isolated several new
stilbenes oligomers [31]. These include the dimer, albiraminol B, which is nearly
identical to a previously known compound, malibatol A (Fig. 9). The only difference
between these two compounds is stereochemistry in the connectivity between the A1
and A2 rings. Notably, malibatol A was also isolated by this group from the same
fraction.

Figure 9. Albiraminol B (left) and malibatol A (right) isolated from Vatica albiramis.

Working with the methanol extract of the whole plant Cyperus longus, which is used
traditionally in Egyptian medicine as a tonic and a diuretic, Morikawa et al. [32], using
bioassay guided fractionation, were able to identify three stilbenes (Fig. 10) [32]. These
include longusol A and B which contain similar connectivity using the common
benzofuran ring to connect the two resveratrol monomers. The carbon skeleton
presented by these two structures has been previously reported as opposing
stereoisomers, as well as re-isolated by this group during the investigation of C. longus.
Longusol C contains a 1,4-dioxane moiety to connect the resveratrol units, however its
stereoisomer was also previously reported. The stereoisomer was again re-isolated by
the group.
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While working with fungal challenged black skin peanut seeds Liu et al. [23] isolated
two new prenylated stilbene dimers, arahypin-11 and arahypin-12, along with the
monomer previously mentioned in Fig. 2. Their isolation of prenylated stilbenes from
fungal challenged peanut seeds follows previous publications, most notably the
previously mentioned Sobolev et al. [17]. Arahypin-11 and -12 can be found in Fig. 11.

Figure 10. Longusol A-C (left to right, respectively) isolated from Cyperus longus.

Figure 11. Arahypin-11 and -12 isolated from fungal challenged black skin peanuts.
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The last dimer isolated contains an aryl coupling between two benzofuran stilbene
monomers. The roots and stems of Vitis amurensis have been used ethnobotanically
as pain relievers, and in this investigation yielded the isolation of the novel dimer [33].
The compound can be found in Fig. 12.

Figure 12. Dimer isolated from the roots and stems of V. amurensis. The compound
contains an aryl carbon-carbon linkage of two benzofuran monomers.

2.4. Stilbene trimers
Of the compounds isolated during this time period, only 4 were stilbene trimers. Three
of these four compounds were isolated from the plant Paeonia suffruticosa by He et al.
[34], two of which are a pair of stereoisomers (Fig.13) [34]. The third compound,
isolated from P. suffruticosa is cis-gnetin H. The three compounds contain the same
carbon skeleton and the resveratrol monomer units are connected by benzofuran rings.
The absolute stereochemistry of the three trimers was determined using NOESY NMR
and circular dichroism [34].
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Figure 13. cis/trans-suffruticosol D and cis-gnetin H (left to right, respectively)
isolated from Paeonia suffruticosa.

As previously mentioned, plants of the genus Gnetum are rich sources of oligomeric
stilbene derivatives [25]. Along with the isolation of the two dimers, macrostachyol C
and D, Sri-in et al. isolated a novel trimer from Gnetum macrostachyum, named
macrostachyol B (Fig. 14) [25]. The structure contains an interesting carbon bridge
creating the bicyclic internal ring system.

Figure 14. Macrostachyol B isolated from Gnetum macrostachyum.

2.5. Stilbene tetramers
Similarly to the stilbene dimers, the majority of the stilbene tetramers contain a
benzofuran moiety. This is due to the fact that the tetramers are primarily ‘dimers of
22

dimers’. As shown in the current review, as well as the most recent other review
reported by Shen et al. [2], the diversity of stilbene dimers is quite extensive. Due to
the number of active functional groups that allow for the ease as well as variety in
polymerization, once a dimer is formed, there are several positions whereby these
newly formed dimers can polymerize to form tetramers of resveratrol. This ease in
polymerization is responsible for the increasing diversity of resveratrol dimers and
tetramers.

Two new tetramers were isolated from Upuna borneensis, conducted by Ito et al. [35].
The group has previously reported a structural variety of resveratrol oligomers from U.
borneensis, while in this report they were investigating the acetone extract of the plant’s
stems. Their work afforded the two new tetramers, upunaphenols O and P (Fig. 15)
[35]. Upunaphenol O consists of the resveratrol dimers ampelopsin A and cis-εviniferin. Additionally both of the dimer-subunits were isolated by the group, whom
had hypothesized that they are indeed the building blocks of the tetramer [35].
Upunaphenol P contains a similar dimer unit to upunaphenol O, however the
determination of whether it is derived from ampelopsin A or B is inconclusive.
Additionally, it contains a unique C–C bridge between the two dimer pieces.
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Figure 15. Upunaphenol O (left) and Upunaphenol P (right) isolated from Upuna
borneensis

Along with the isolation of the two dimers, macrostachyol C and D, and the trimer
macrostachyol B, this group also isolated a novel tetramer from Gnetum
macrostachyum, macrostachyol A (Fig.16) [25]. Macrostachyol A differs from other
common tetramers, as based on the bonding pattern it does not appear to be a dimer of
a dimer. Instead, the bonding suggests that macrostachyol A is derived from latifolol,
a resveratrol trimer, combined with yet another resveratrol unit through oxidative
coupling [25]. It is noteworthy to add that this group also isolated latifolol, which adds
credibility of their oxidative coupling hypothesis.

Figure 16. Macrostachyol A isolated from Gnetum macrostachyum.
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The next two resveratrol tetramers return to the commonality of a dimer of dimers and
include cajyphenol A and B which were isolated from Cayratia japonica by Bao et al.
[36] (Fig. 17). These two tetramers contains the same carbon skeleton, however differ
in their attachment of the two dimer sub-pieces. Additionally the southern portion of
each the two molecules contains opposing relative stereochemistry.

Figure 17. Cajyphenol A (left) and cajyphenol B (right) isolated from Cayratia
japonica.
The ﬁnal resveratrol tetramer isolated during the time of this review, is also the only
tetramer that displays a carbon-symmetric structure (Fig. 18). Vateriaphenol F was
isolated from the leaves of Vateria indica by Ito et al. [27]. The dimer of dimers is
constructed from two ε-viniferin pieces. In this example, the use of the furan moiety
has been used to polymerize each step of the oligomer from the resveratrol monomers.
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Figure 18. Vateriaphenol F isolated from Vateria indica.
2.6. Stilbene hexamer
There was only one hexamer isolated during the time period covered by this review,
and it is only the ﬁfth instance of a resveratrol hexamer being isolated from a natural
source (Fig. 19). This hexamer was isolated from the acetone extract of Vatica
albiramis stems by Abe et al. [31]. The structure consists of a tetramer, vacticanol A,
and a dimer unit. Additionally it is important to note the 1,2-aryl shift which occurred
in resveratrol F has rarely been seen in isolated oligomers [31].

Figure 19. Albiraminol A isolated from Vatica albiramis.
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2.7. Norstilbene
An interesting structure, longusone A, was isolated from the methanol extract of the
whole plant Cyperus longus by Morikawa et al. [32] (Fig. 20). When compared to those
structures in this review, this compound has several unique features.

As stated

previously, the majority of the stilbene oligomers were constructed using resveratrol as
the monomeric unit.

However, the building block in this molecule contains an

additional hydroxyl functional group. The presence of the hydroxyl group in the ortho
position on the southern-most di-substituted ring, although uncommon, is not
improbable as it is present from the portion of resveratrol that is constructed from the
shikimate biosynthetic pathway. Additionally this compound contains a tropilene
moiety, in which for the purpose of this review, had not been previously observed in
natural stilbenes. The author, Morikawa et al. [32], describes this molecule as a
norstilbene dimer, however it seems unlikely that the molecule’s origin is a true stilbene
dimer (Fig. 20).

Figure 20. Longusone A isolated from Cyperus longus.
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2.8. O-glycosylated stilbenes
The previous stilbenes reported in this review have not been glycosylated. During the
period in which this review covers, there were 13 O-glycosylated structures reported
of which, four were monomers, six dimers, and three tetramers. Like many other classes
of compounds, the most common sugar moiety added is glucose and in the case of this
review, all of the sugar moieties added through O-glycosylation were glucose.

Upon fractionation of the aerial portions of the Mongolian medicinal plant, Scorzonera
radiata, Wang et al. [37] isolated four new glycosylated monomers (Fig.21) [37].
These monomers differ from the typical resveratrol monomer with the addition of the
acetate unit at C1, as well the substitution pattern in ring B. Additionally, several of
these monomers have methyl modiﬁcations at various locations generating methoxyl
functional groups. The group also isolated a dimer of Fig. 21’s compound 1, which was
connected through a C–C bond and the 5ˊ carbon (Fig. 21) [37].

Figure 21. Four glycosylated monomers and a dimer isolated from Scorzonera
radiate.
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Two new glycosylated compounds were isolated in the leaves of Vateria indica by Ito
et al. [27]. One of the structures, a dimer, is previously mentioned in this review as
having an aglycone that had previously not been isolated in nature (Fig. 5). The group
also isolated a tetramer with an aglycone, consistent with that of hopeaphenol, a dimer
of two ampelopsin units (Fig. 22) [27].

Figure 22. Vaterioside B isolated from Vateria indica.

Two publications from the same group, Abe et al. [31, 38], resulted in the ﬁnal six Oglycosylated stilbenes isolated in the time frame of this review [31, 38]. All six were
isolated from the stems of Vatica albiramis and named vatalbinosides A-F (Fig. 23).
The group isolated 4 dimers and 2 tetramers. While these glycosylated versions are
newly isolated compounds, each of the compounds respective aglycones are previously
described skeletons.
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Figure 23. Vatalbinosides A-F isolated from Vatica albiramis.

2.9. C-glycosylated stilbenes
While O-glycosylated structures are much more common, occasionally C-glycosylated
structures are also reported among stilbenoids. Abe et al. [39] isolated four new Cglycosylated structures from Hopea parviﬂora, namely, 2 pentamers, a trimer, and a
dimer.

These compounds have been named hopeasides A-D (Fig.24).

The two

pentamers are the ﬁrst C-glucopyranosyl resveratrol oligomers isolated to date.
Moreover, they are stereoisomers of each other but the orientation in which the two
differ remains unknown. The orientation, interestingly, is in regard to the orientation
of the C–C bonds between 7e-8e-9e. Theoretically, these are sp3 hybridized freely
rotatable bonds, however due to the steric hindrance within the molecule, rotation is
restricted creating the two stereoisomers.
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Figure 24. Hopeasides A-D (left to right) isolated from Hopea parviflora.

3. Biological activity of stilbenoids
Historically, there has been signiﬁcant work done on the role of stilbenes and their
activity as anti-bacterial agents, antioxidants, several anticancer properties, NFκB and
hemeoxygenase moderators. For example, kobophenol-A and -B are tetrastilbenes that
were ﬁrst isolated from Carex kobomugi and Carex pumila, respectively. These
compounds have been shown to have moderate inhibitory activity against
Staphylcoccus aureus [3, 4]. Due to the inherent (poly)phenolic structure of stilbenes,
there has been extensive research conducted on their role as antioxidants. Reactive
oxygen species (ROS) are generated in bio-organic redox processes. Deregulation of
this dynamic biological process leads to oxidative stress, which has been linked to
many chronic human diseases including cancer, diabetes, and cardiovascular diseases
[5].The direct efﬁcacy of stilbenes ability for the scavenging of ROS, or induce
NADPH oxidase and xanthine oxidase inhibition, however still remains unclear [1].
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An additional biological property that stilbenes exhibit is the inhibition of
topoisomerase II. Topoisomerases play a critical role in the unwinding of coiled DNA
during cellular transcription [6]. Upon discovering this mechanism for oligomeric
stilbenes, Yamada et al. [6] conducted a study on over 40 stilbenes and their ability to
inhibit topoisomerase II and identiﬁed α-viniferin as being highly active. In addition to
its ability to inhibit topoisomerase II, α-viniferin has also been reported to not induce
apoptosis, but interestingly arresting cell-cycle in the S-phase in human colon
tumorigenic cells [7].

Resveratrol has also been implicated in the modulation of several proteins involved in
a variety of degenerative diseases. It has been shown that resveratrol down regulates
NFκB, an important protein complex involved in cell survival and proliferation.
Incorrect regulation of NFκB has been linked to cancer, inﬂammatory and autoimmune
diseases, septic shock, viral infection, and improper immune development [8, 9].
Resveratrol has also been linked to moderate hemeoxygenase activity, which catalyzes
the cleavage of heme to form iron, CO and bilirubin. Incorrect activity within
hemeoxygenase has been linked to Parkinson’s and Alzheimer’s diseases [8, 9].
Finally, resveratrol has been shown to ameloriate some of the problems associated with
type II diabetes, such as myocardial ischemia [40].

More recently, resveratrol and some of its analogs, have been linked to anti-aging
properties. It was shown that through mimicking caloric restriction, resveratrol
prolonged the lifespan of budding yeast, Saccharomyces cerevisiae. Supporting results
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followed with additional organisms, including the nematode, Caenorhabditis elegans,
the fruit ﬂy, Drosophila melanogaster, and the honey bee, Apis mellifera [41–44]. With
mammals, the ﬁrst experiments carried out in mice conﬁrmed that resveratrol mimicked
the effects of caloric restriction including reduced albumin uria, decreased
inﬂammation, and apoptosis in the vascular endothelium, increased aortic elasticity,
greater motor coordination, reduced cataract formation, and preserved bone mineral
density [45].

Since aging is a complex process, one could anticipate that the role that stilbenes play
in exerting anti-aging effects could be achieved by targeting multiple physiological
processes. In fact, resveratrol appears to ﬁt such a hypothesis, although its exact
mechanism is not yet fully established. The most intriguing observation linking
resveratrol with longevity was its ability to activate members of the sirtuin (SIRT)
family, especially SIRT1 [41]. SIRT1 has been shown to mediate the beneﬁcial effects
of caloric restriction on longevity extension [46]. Resveratrol was also shown to reverse
a variety of age-related conditions by counteracting mitochondrial dysfunction and
metabolic diseases [47]. Several of these effects are SIRT1-dependent, but many others
are mediated through independent pathways, such as a cAMP-PKA-AMPKA cascade
[48].

4. Summary and concluding remarks
In summary, this review covers the chemical structures of natural stilbenoids isolated
and identiﬁed from 2009–2013. It is apparent that stilbenes are an exciting chemical
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class of natural polyphenolic compounds with a unique carbon backbone that allows
them to polymerize into complex structures and to be biologically active in a variety of
systems. They have been implicated in the inhibition of growth of microbes, as well as
to be strong anti-oxidants. In addition, this class of compounds has the ability to inhibit
the growth of cancer cells in vitro. These compounds display great potential in their
chemical diversity but understanding of their role in human health prevention and
disease risk reduction would need further studies into their in vivo biological potential
and mechanisms of action.
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Abstract
Two new phenolics, a stilbenoid, vulpinoideol A (1), and a chalcone, vulpinoideol B
(2), along with ten known compounds (3-12) were isolated from Carex vulpinoidea
seeds. The structures of compounds 1-12 were elucidated based on spectrometric and
spectroscopic analyses including HRESIMS, 1D and 2D NMR data. All compounds
were evaluated for their tyrosinase enzyme inhibitory activities.

39

1. Introduction
The Carex genus (family, Cyperaceae) contains over 2000 species [1], but the majority
of these remain largely uninvestigated for their phytochemical constituents. This is
unfortunate, considering that the Cyperaceae family is one of the few plant families
known to produce stilbenoid derivatives, a sub-class of phenolic compounds which
exhibit significant structural diversity and a wide range of biological activities [2, 3].
Over the past few years, our group has studied Carex species found in the northern
regions of the United States, which have yielded several bioactive phenolic
constituents, including resveratrol oligomers and other stilbenoids [4, 5].

Hyperpigmentary disorders, such as melasma and freckles, are due to the abnormal
accumulation of melanin. The tyrosinase enzyme has been implicated as a key enzyme
in melanogenesis, as it initiates an enzymatic cascade through the conversion of
tyrosine and 3, 4-dihydroxyphenylalanine (DOPA) into DOPA-quinone [6, 7].
Notably, plant natural products, in particular, phenolic compounds, have shown great
promise as tyrosinase inhibitors, a primary example being the phenolic glycoside,
arbutin, which is widely used for commercial cosmetic applications [8, 9]. Moreover,
several phenolic sub-classes, including flavonoids, chalcones, and stilbenoids, are
known to be tyrosinase inhibitors [10-12]. Therefore, in the current study, we sought
to: 1) isolate and chemically characterize the constituents from the seeds of the
previously uninvestigated Carex vulpinoidea and, 2) evaluate the isolates for their antityrosinase activities.
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Herein we report the isolation and structure elucidation of two new phenolics, namely,
vulpinoideols A (1) and B (2) (Figure 1), along with ten known compounds (3-12)
(Figure 2) from C. vulpinoidea seeds. All of the isolates were evaluated for their
tyrosinase inhibitory activity, along with the positive control, arbutin.

Compound 1 had a molecular formula of C25H30O8 from the HRESIMS data
corresponding to the quasimolecular ion at m/z 481.1835 [M + Na]+ (Figure 3). The 1H
NMR spectrum (Figure 4) revealed a para- substituted aromatic ring system (ring A)
with ortho-coupled- protons at δH 7.34 (2H, J = 8.5Hz) and δH 6.78 (2H, J = 8.5Hz);
a second aromatic spin system (ring B) with meta-coupled protons at δH 6.74 (1H, J =
2.1Hz) and δH 6.60 (1H, J = 2.1Hz); a trans-ethylene system with protons at δH 6.86
(1H, J = 16.3Hz) and δH 7.14 (1H, J = 16.3Hz); an olefinic proton at δH 5.14 (1H, t J
= 6.4Hz); one methylene, and two methyl groups and characteristic signals of a βglucopyranose moiety, for which the resonance of the anomeric proton was at δH 4.86
(J = 7.1Hz).

The 13C NMR data (Figure 5) coupled with the HSQC spectra (Figure 6) revealed the
presence of 25 carbons, and confirmed the presence of two aromatic rings, containing
three oxygen-linked carbons, two alkene double bonds, and a sugar moiety. Detailed
analysis of the 2D NMR data (including HSQC and HMBC) (Figures 6 and 7) allowed
the structure elucidation of compound 1 (Figure 1). The data revealed the presence of
an isoprene group, which was confirmed through the following HMBC correlations,
H-18/H-19 with C-16/C-17 and H-15 with C-16/C-17.
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The placement of the isoprene group at position C-14 was based on HMBC correlations
of H-15 with C-9/C-13/C-14 (Figure 1). The β-glucopyranose moiety was placed at
position C-13 based on the HMBC correlation of the anomeric proton H-1a to C-13.
Further HMBC correlations, including H-12 with C-10/C-11, and H-10 with C-12/C13/C-14, allowed for the arrangement of substituents in ring B. Additional key HMBC
correlations, H-7 to C-1/C8 and H-8 to C/-7C-10/C-14 indicated the presence of a C6C2-C6, 1, 2-diphenylethylene moiety. This backbone is characteristic of a monomeric
stilbene derivative and, therefore, compound 1 was elucidated as depicted and assigned
the common name of vulpinoideol A.

Compound 2 (vulpinoideol B) was identified with a molecular formula of C26H32O9,
corresponding to a quasimolecular ion peak at m/z 511.1937 [M + Na]+ (Figure 9).
Compared with compound 1, vulpinoideol B (2) had the addition of a carbonyl carbon
(C-8a, 206.2Hz), as well as the saturation of the alkene linkage between the aromatic
spin systems, δH 2.90 (2H, t) and δH 3.16 (2H, t) (Figure 10). These differences
suggested the backbone of a saturated chalcone. Similar to vulpinoideol A (1),
vulpinoideol B (2) retained the ortho-coupled aromatic protons (δH 7.04, 2H, J = 8.2Hz
and δH 6.69, 2H, J = 8.2Hz). However, its second aromatic system contained two
isolated protons at δH 6.62 (1H, s) and δH 7.72 (1H, s) (Figure 11).

The 13C NMR (Figure 12) and HMBC data (Figure 13) were again indicative of an
isoprene substituent, as well as a β-glucopyranose moiety, which had its anomeric
proton at δH 5.02 (J = 6.9 Hz).

The placement of the isoprene unit at C-13 was
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confirmed using similar HMBC correlations as vulpinodeol A (1) i.e. H-15 with C14/C-13/C-12. Additionally, the HMBC correlation between the anomeric proton of
the sugar, H-1a and C-12 allowed for the placement of the sugar moiety at C-12. The
HMBC correlations H-14 and H-8 with C-8a, and H-7 with C-8/C-5 confirmed the
structure of the backbone (Figure 1).

The inhibitory effects of all the isolates on mushroom tyrosinase enzyme were
evaluated along with arbutin, the positive control. Among the isolates, only the new
compound, vulpinoideol B (2), as well as the known compounds, hopeaphenol (4) and
the α-hydroxychalone (8) were more active than arbutin (IC50 values of 49.4, 6.1, 29.1
vs 72.6µM, respectively). The IC50 values of all the other isolates, including the new
compound, vulpinoideol A (1) (IC50 = 151µM), exceeded 100µM.
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2. Experimental
General: Semi-preparative HPLC separations were performed on a Hitachi Elite
LaChrom system consisting of an L2130 pump, an L-2200 autosampler, and an L-2455
diode array detector, all operated by EZChrom Elite software, using a Phenomenex
C18 column (250 × 10mm, 5μm), with a flow rate of 3mL/min. Medium pressure liquid
chromatography (MPLC) separations were carried out on a prepacked C18 column (37
× 5.5cm; ﬂow rate 3mL/min), and a liquid chromatography DLC-10/11 Isocratic pump
(D-Star Instruments, Manassas, VA, USA). All solvents were either ACS or HPLC
grade and were obtained from Wilkem Scientiﬁc (Pawcatuck, RI, USA). Sephadex
LH20 resin (Amersham Biosciences) was packed in a glass column (3 × 70cm) and
eluted with a 100% methanol mobile phase. HRESIMS data was acquired using a
Synapt G2-S QTOF mass spectrometer (Waters, Milford, MA).

Plant material: The seeds of Carex vulpinoidea were collected on July 22, 2010 at the
Susquehanna University CEER (Center for Environmental Education and Research)
property in Pennsylvania, USA. A voucher sample (CM# 507015) is deposited at the
Carnegie Museum Herbarium in Pittsburg (PA, USA).

Extraction and separation: The seeds were ground (39.6g) and exhaustively extracted
sequentially with hexanes, acetone, and methanol (each 3 times, 150mL per solvent for
24h, each extraction). The acetone extract (2.03g) was subjected to C18 reverse phase
MPLC with a gradient solvent system of MeOH: H2O (40:60-100:0 v/v) to afford
fractions 1-8. Fraction 1 (575.3mg) was eluted through the Sephadex LH20 column to
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afford fractions 9-15. Fraction 12 (426.6mg) was subjected to reverse phase C18
MPLC (gradient, MeOH:H2O, 30:70-50:50, v/v) to yield hopeaphenol (4, 18.6mg) [13]
and grandiphenol A (5, 24.1mg) [14].

Fraction 5 (19.9mg) was eluted through the Sephadex LH20 column to afford subfractions 16-28. Two compounds, 3,5,5′,7′-tetrahydroxyflavone (6, 3.4mg) [15] and a
benzofuran (3, 2.1mg) [16], were isolated from fraction 22 (30.4mg) using semipreparative reverse phase C18 HPLC (isocratic, 55:45 MeOH:H2O, v/v). Similarly,
fraction 6 (384.7mg) was chromatographed on the Sephadex LH20 column to afford
sub-fractions 29-35, and further separation of sub-fraction 30 (50.9mg) by C18 HPLC
(gradient, MeOH:H2O, 50:50-100:0, v/v) yielded 3′,4′,7-trihydroxyflavone (7, 2.7mg)
[17], vulpinoideol A (1, 3.4mg) and α-hydroxychalone (8, 4.4mg) [18]. Butein (9,
15.1mg) [19] was isolated from sub-fraction 32 by C18 HPLC (isocratic, MeOH:H2O,
77:23, v/v). Methylated naringenin (10, 1.8mg) [20], vulpinoideol B (2, 2.2mg), and
luteolin (11, 4.8mg) [5] were obtained from fraction 6 by C18 HPLC (gradient,
MeOH:H2O, 60:40 – 70:30, v/v). Bavachalcone (12, 1.3mg) [21] was isolated from
fraction 9 using Sephadex LH20, followed by C18 HPLC purification (isocratic,
MeOH:H2O, 70:30, v/v).

Vulpinoideol A (1)
White amorphous solid.
UV (MeOH) λmax: 305, 210 nm.
1
H NMR and 13C NMR: Table 1.
HRESIMS: m/z [M + Na]+ calc. for C25H30O8: 458.5009; Found: 481.1835.
Vulpinoideol B (2)
Light yellow amorphous solid.
UV (MeOH) λmax: 330, 275, 210 nm.
45

1

H NMR and 13C NMR: Table 1.
HRESIMS: m/z [M + Na]+calc. for C26H32O9: 488.5269; Found: 511.1937.
Tyrosinase inhibition assay: The tyrosinase assay was carried out similarly to Zhang
and co-workers [22]. Briefly, mushroom tyrosinase, L-tyrosine and the positive
control, 4-hydroxyphenyl β-D-glucopyranoside (arbutin) were purchased from SigmaAldrich (St. Louis, MO). Tyrosinase inhibition assays were performed in 96-well
microplate format using a SpectraMax M2 microplate reader (Molecular Devices, CA).
Test samples were dissolved in DMSO at a concentration of 2.0mM and then diluted
to different concentrations with phosphate buffer (0.1M, pH 6.8). Each well contained
40μL of sample with 80μL of phosphate buffer solution, 40μL of tyrosinase
(100units/mL), and 40μL L-tyrosine (2.5mM). The mixture was incubated for 30min
at 37°C and absorbance was measured at 490nm. Each sample was accompanied by a
blank, containing all components except L-tyrosine. Arbutin was used as the positive
control. The results were compared with a negative control consisting of 10% DMSO
in place of the sample. The percentage of tyrosinase inhibition was calculated as
follows:
[(ΔAcontrol − ΔAsample)/ ΔAcontrol] × 100

46

3. Acknowledgments
The plant material was collected by Kristen Brown (currently at University of Maine)
and authenticated by Bonnie Isaac of the Carnegie Museum Herbarium. We would like
to thank Dr. Ke Liu from the University of Pittsburgh for assistance with the mass
spectral data.

47

References
[1]

A.A. Reznicek. Can. J. of Bot. 1990, 68, 1409-1432.

[2]

A. Vannozzi, I.B. Dry, M. Fasoli, S. Zenoni, M. Lucchin. BMC Plant Bio.
2012, 12, 130-148.

[3]

D.B. Niesen, C. Hessler, N.P. Seeram. J. of Berry Res. 2013, 3, 181-196.

[4]

A. González-Sarrías, S. Gromek, D.B. Niesen, N.P. Seeram, G.E. Henry. J. of
Ag. Food Chem. 2011, 59, 8632-8638.

[5]

L. Li, G.E. Henry, N.P. Seeram. J. of Ag. Food Chem. 2009, 57, 7282-7287.

[6]

V.J. Hearing and K. Tsukamoto. FASEB Journal. 1991, 5, 2902−2909.

[7]

H. Wu and H.Y. Park. Biochem. Biophys. Res. Comm. 2003, 311, 948−953.

[8]

Z-M. Hu, Q. Zhou, T-C. Lei, S-F. Ding, S-Z. Xu J. Derm. Sci. 2009, 55, 179184.

[9]

K. Maeda and M. Fukuda. J. of Pharm. and Exp. Ther. 1996, 276, 765-769.

[10]

X. Hu, J-W. Wu, M. Wang, M-H. Yu, Q-S. Zhao, Y-H. Wang, A-J. Hou. J. of
Nat. Prod. 2012, 75, 82-87.

[11]

N.T. Nguyen, M.H.K. Nguyen, H.X. Nguyen, N.K.N Bui, M.T.T. Nguyen. J.
of Nat. Prod. 2012, 75, 1951-1955.

[12]

F.W-K. Cheung, A.W-N. Leung, W.K. Liu, C-T. Che. J. of Nat. Prod. 2014,
77, 1270-1274.

[13]

J. Ito, M. Niwa, Y. Oshima. Heterocycles. 1997, 49, 1809-1813.

[14]

T. Ito, T. Tanaka, M. Iinuma, K-I Nakaya, Y. Takahashi, R. Sawa, J. Murata, D.
Darnaedi. Helvetica Chimica Acta. 2004, 87, 470-495.

[15]

U. Anthoni, E.D. Rosalba, P.H. Nielsen, C. Christophersen. Acta Chemica
Scandinavica. 1998, 52, 1243-1246.

[16]

R. Dupont, P. Cotelle. Tetrahedron. 2001, 57, 5585-5589.

[17]

Q. Wang, S. Ji, S-W. Yu, H-X. Wang, X-H. Lin, T-T. Ma, X. Qiao, C. Xiang, M.
Ye, D-A. Guo. Fitoterapia. 2013, 85, 35-50.

[18]

R. Metuno, F. Ngandeu, A.T. Tchinda, B. Ngameni, G.D.W.F. Kapche, P.C.
Djemgou, B.T. Ngadjui, M. Bezabih, B.M. Abegaz. Biochem. System. and Ecol.
2008, 36, 148-152.

[19]

G. Nonaka, Y. Goto, J. Kinjo, T. Nohara, I. Nishioka. Chem. Pharm. Bull. 1987,
35, 1105–1108.

[20]

J. Zhao, D. Huan-Xing, Z. Deng-Gao, W. Chun-Ming, K. Gao. J. of Pharmacy
and Pharmacology. 2011, 64, 1785-1792.

[21]

H. Wang, Z. Yan, Y. Lei, K. Sheng, Q. Yao, K. Lu, P. Yu Tet. Lett. 2014, 55,
897-899.
48

[22]

X. Zhang, X. Hu, A. Hou, H. Wang. Bio. Pharm. Bull. 2009, 32, 86-90.

49

Table 1 1H NMR and 13C NMR data of Vulpinoideols A and B.

No.
1
2
3
4
5
6
7
8
8a
9
10
11
12
13
14
15
16
17
18
19
1a
2a
3a
4a
5a
6a

Vulpinoideol A
δC
δH (mult, J in Hz)
127.3
7.34 (2H, d, 8.5)
115.1
6.78 (2H, d, 8.5)
157.0
115.1
6.78 (2H, d, 8.5)
127.3
7.34 (2H, d, 8.5)
129.3
129.6
6.86 (d, 16.3)
123.4
7.14 (d, 16.3)
**
**
138.4
105.5
6.74 (d, 2.1)
155.7
101.9
6.60 (d, 2.1)
156.3
120.0
24.0
3.40/3.56 (m)
124.4
5.14 (t, J=6.4)
129.4
16.8
1.83 (3H, s)
24.5
1.68 (3H, s)
101.5
4.86 (7.1)
73.5
3.50 (m)
76.7
3.44 (m)
69.8
3.44 (m)
76.9
3.49 (m)
61.1
3.74/3.94 (dd)
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δC
130.3
116.1
156.8
116.1
130.3
133.0
31.3
41.5
206.2
115.1
164.3
103.3
162.9
123.5
131.8
28.5
123.4
133.9
17.9
25.9
101.3
78.3
74.8
71.2
78.3
62.3

Vulpinoideol B
δH (mult, J in Hz)
7.04 (2H, d, 8.2)
6.69 (2H, d, 8.2)
6.69 (2H, d, 8.6)
7.04 (2H, d, 8.2)
2.90 (2H, t)
3.16 (2H, t)
6.62 (s)
7.72 (s)
3.28 (m)
5.31 (t)
1.71 (3H, s)
1.75 (3H, s)
5.02 (6.9)
3.51
3.48
3.44
3.51
3.71, 3.90

Table 2: Tyrosinase Enzymatic Inhibition Activity of two new compounds,
Vulpinoideols A and B, as well as other highlighted C. vulpinodea isolates. Arbutin
(*) has been used a positive control.

Compounds

IC50 (µM)

Std dev.

Vulpinoideol A (1)

150

6.0

Vulpinoideol B (2)

49.4

13

Hopeaphenol (4)

6.10

1.2

Grandiphenol A(5)

174

5.8

α-hydroxychalcone (8)

29.1

0.3

Bavachalcone (12)

122

7.9

Arbutin*

72.6

7.9
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Figure 1: Selected HMBC correlations (HC) of vulpinoideol A (1) and
vulpinoideol B (2) (top to bottom, respectively).
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Figure 2: Known isolates from C. vulpinoidea
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Figure 3. Vulpinoideol A. High Resolution Mass Spectrometry Data.
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489

m/z

Figure 4. Vulpinoideol A -1H NMR spectrum. Data was measured in CH3OD at 500
MHz (1H) and 125 MHz (13C).
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Figure 5. Vulpinoideol A- 13C NMR spectrum. Data was measured in CH3OD at 500
MHz (1H) and 125 MHz (13C).
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Figure
6. Vulpinoideol A - NMR HSQC spectrum. Data was measured in CH3OD at 500
MHz (1H) and 125 MHz (13C).
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Figure 7. Vulpinoideol A - NMR HMBC spectrum. Data was measured in CH3OD at
500 MHz (1H) and 125 MHz (13C).
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Figure 8. Vulpinoideol A - NMR COSY spectrum. Data was measured in CH3OD at
500 MHz (1H) and 125 MHz (13C).
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Figure 9. Vulpinoideol B. High Resolution Mass Spectrometry Data.
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519.1808

m/z
519

Figure 10 Vulpinoideol B – 1H NMR spectrum. Data was measured in CH3OD at 500
MHz (1H) and 125 MHz (13C).
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Figure 11. Vulpinoideol B - NMR HSQC spectrum. Data was measured in CH3OD at
500 MHz (1H) and 125 MHz (13C).
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Figure 12 Vulpinoideol B - 13C NMR spectrum. Data was measured in CH3OD at 500
MHz (1H) and 125 MHz (13C).
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Figure 13. Vulpinoideol B - NMR HMBC spectrum. Data was measured in CH3OD at
500 MHz (1H) and 125 MHz (13C).
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Figure 14. Vulpinoideol B - NMR COSY spectrum. Data was measured in CH3OD at
500 MHz (1H) and 125 MHz (13C).
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CHAPTER 2
GALLOTANNINS

Manuscript 3 appears as published:
Structure Activity Related, Mechanistic, and Modeling Studies of Gallotannins
containing a Glucitol-Core and α–Glucosidase. Ma, Hang; Wang, Ling; Niesen, Daniel
B.; Cai, Ang; Cho, Bongsup P.; Tan, Wen; Gu, Qiong; Xu, Jun; and Seeram, Navindra
P. (2015). RSC Advances. 5, 107904-107915………………………………………...70
Synthesis of tetragalloylglucitol (maplexin J)…………………………………...….108
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ABSTRACT
The incidence of type 2 diabetes mellitus is increasing rapidly worldwide and has
become a significant public health burden [1]. Among various strategies used for type
2 diabetes management, clinical α-glucosidase inhibitory drugs, such as acarbose, are
utilized to inhibit the activity of carbohydrate hydrolyzing enzymes and thus decreasing
postprandial hyperglycemia [2]. Over the past decade, there has been renewed scientific
interest in identifying plant-based α-glucosidase inhibitors for the treatment and
management of diabetes. Moreover, since these purified natural products could serve
as important leads in the development of new classes of glucosidase inhibitors, the
synthesis of analogs have also attracted a considerable amount of scientific interest [3].

Our laboratory previously isolated a series of α-glucosidase inhibitory gallotannins,
named maplexins A-I, from the red maple (Acer rubrum) species [4, 5]. These
compounds contained mono-, di-, and tri-galloyl substituents located at different
positions on a 1, 5-anhydro-D-glucitol moiety. Interestingly, the α-glucosidase
inhibitory activities of these maplexins increased with the number of galloyl
substituents, and a trigalloyl substituted maplexin was 20-fold more potent than the
clinical drug, acarbose [5]. However, since a tetra-galloyl substituted maplexin was not
obtained in our previous natural product isolation studies, a total synthesis is required
to further evaluate the class of compounds and its α-glucosidase inhibitory activity.
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To investigate the ligand-enzyme interaction, several biophysical methods including
binding domains, modifications of hydrophobic surfaces, and secondary structural
conformational changes were explored. Enzymatic kinetics and biophysical tools,
including isothermal titration calorimetry (ITC), fluorescence, and circular dichroism
(CD) spectroscopic methods, were used to elucidate the inhibitory mechanisms of the
gallotannins against the α-glucosidase enzyme. Computational manipulation of
homology modeling and molecular docking were also performed to support the
prediction of binding interactions between the gallotannins and α-glucosidase.

With a synthetic route established for maplexins E and J, through a collaborative
publication with Dr. Hang Ma (Manuscript 3), we were able to continue the
investigation of the ligand-enzyme interaction of the class of gallotannins and their
target enzyme α-glucosidase. As a collaborative publication, Dr. Ma’s contribution
specifically, sections: 2.2 measurements of α-glucosidase inhibitory assay, 2.3
kinetics of α-glucosidase inhibition, 2.5 hydrophobic interactions of α-glucosidase
using bis-ANS, 2.6 mircular dichroism (CD) spectroscopy, table 1, table 3, figure 2,
figure 4, and the resultant analysis of that data found in sections: 2.2, 2.3, 2.5, 2.6,
table 1, table 3, figure 2,, appear in Dr. Ma’s dissertation (Dr. Hang Ma Dissertation,
Phytochemical and biological investigation of gallotannins from red maple (Acer
rubrum) species, University of Rhode Island, 2014).
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Abstract
Gallotannins containing a glucitol core, which are only produced by members of the
maple (Acer) genus, are more potent α-glucosidase inhibitors than the clinical drug,
acarbose. While this activity is influenced by the number of substituents on the
glucitol core (e.g. more galloyl groups leads to increased activity), the mechanisms
of inhibitory action are not known.

Herein, we investigated ligand-enzyme

interactions and binding mechanisms of a series of ‘glucitol-core containing
gallotannins (GCGs)’ against the α-glucosidase enzyme. The GCGs included
ginnalins A, B and C (containing two, one, and one galloyl/s, respectively), maplexin
F (containing 3 galloyls) and maplexin J (containing 4 galloyls). All of the GCGs
were noncompetitive inhibitors of α-glucosidase and their interactions with the
enzyme were further explored using biophysical and spectroscopic measurements.
Thermodynamic parameters (by isothermal titration calorimetry) revealed a 1:1
binding ratio between GCGs and α-glucosidase. The binding regions between the
GCGs and α-glucosidase, probed by a fluorescent tag, 1,1′bis(4-anilino-5napththalenesulfonic acid, revealed that the GCGs decreased the hydrophobic
surface of the enzyme. In addition, circular dichroism analyses showed that the
GCGs bind to α-glucosidase and lead to loss of the secondary α-helix structure of
the protein. Also, molecular modeling was used to predict the binding site between
the GCGs and the α-glucosidase enzyme. This is the first study to evaluate the
mechanisms of inhibitory activities of gallotannins containing a glucitol core on αglucosidase.
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1. Introduction
In mammals, enzymes involved in the carbohydrate metabolic pathways have been
the therapeutic targets for various diseases, including diabetes, cancer, and viral
infections [1-3]. Among these enzymes, the group of glucosidases (EC 3.2.1.20)
plays a crucial role in carbohydrate metabolism by catalyzing the cleavage of
glycosidic linkage of oligosaccharides or glycoconjugates to release monosaccharides [4].

Inhibition of glucosidase hinders glucose absorption and

consequently decreases postprandial blood glucose levels. Development of
αglucosidase inhibitors, as a class of antidiabetic medications for type II diabetes
mellitus (T2DM), has attracted significant scientific attention [5]. In fact, several
synthetic α-glucosidase inhibitors (AGIs), including acarbose, miglitol, and
voglibose, are widely used as clinical treatment options for T2DM [6, 7]. However,
adherence to synthetic AGI, as prescription medications, has suffered due to
prominent undesirable side effects, including flatulence, diarrhea, and abdominal
pain [8]. Conversely, naturally occurring AGIs, isolated from medicinal plants and
medicinal foods, offer an attractive dietary strategy for T2DM management since
they tend to be safe, and have fewer adverse effects than synthetic AGIs [9].

The maple (Acer) genus is widely regarded for certain species including the sugar
maple (Acer saccharum) and red maple (Acer rubrum) species, the sap of which are
collected and concentrated to produce the natural sweetener, maple syrup [10].
Interestingly, in the plant kingdom, only members of the maple (Acer) genus are
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reported to produce gallotannins containing a glucitol instead of a glucose core
which is most commonly found in gallotannins [11-16].

Our group and others have shown that these ‘glucitol-core containing gallotannins
(GCGs)’ display potent α-glucosidase inhibitory properties which is influenced by
the number, type, and location of substituents on their glucitol core [14-17]. In
addition, our group showed that a red maple bark extract, enriched in GCGs, was
similar in activity as acarbose, in lowering blood glucose in an animal model [18].
Therefore, GCGs represent an interesting polyphenol sub-class of plant natural
products which show great promise as natural AGIs.

In our group’s research efforts to identify natural AGIs, we reported on a series of
new GCGs, named maplexins E-I, from the red maple (Acer rubrum) species [1416]. The GCGs feature different numbers and positions of galloyl groups attached
to a 1,5-anhydro-D-glucitol core and exhibited 20-fold higher potency than acarbose
which increased with the number of galloyl groups on the glucitol moiety. However,
since these naturally occurring/isolated GCGs only contained three galloyl groups at
the most, in an effort to broaden our test panel of GCGs, we synthesized a
tetragalloylglucitol analog assigned the common name of maplexin J. Indeed,
maplexin J was found to be three times more potent than maplexins E and F (contain
trigalloyls), and 70 times more potent than the competitive inhibitor acarbose (see
Table 1), confirming our previous SAR observations. In the current study, we have
focused our attention on investigating the mechanisms of inhibitory actions of these
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GCGs on the α-glucosidase enzyme. This research project was also prompted, in
part, by the fact that other natural AGIs, such as 1-deoxynojirimycin, resveratrol,
and oxyresveratrol, show different mechanisms of action against α-glucosidase [2021].

The mechanisms of inhibition of compounds on the α-glucosidase enzyme can be
investigated by several biophysical methods including binding domains,
modifications of hydrophobic surfaces, and secondary structural conformational
changes of enzymes induced by binding ligands [21]. In this study, enzymatic
kinetics and biophysical tools, including isothermal titration calorimetry (ITC),
fluorescence, and circular dichroism (CD) spectroscopic methods, were used to
elucidate the inhibitory mechanisms of the GCGs against the α-glucosidase enzyme.
Computational manipulation of homology modeling and molecular docking were
performed to support the prediction of binding actions between the GCGs and the
αglucosidase enzyme.
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2. Experimental
2.1 Chemicals.
α-Glucosidase (EC 3.2.1.20) from Saccharomyces cerevisiae, p-nitrophenyl-α-Dglucopyranoside (pNPG), and bis-8-anilinonaphthalene-1-sulfonate (bis-ANS) were
purchased from Sigma Aldrich (St. Louis, MO). All other chemicals were analytical
reagent grade and were purchased from Sigma Aldrich, unless otherwise specified.
The naturally occurring GCGs (Figure 1): ginnalin A (GA; contains two galloyls),
ginnalin B (GB; contains one galloyl), ginnalin C (GC; contains one galloyl) and
maplexin F (MF; contains three galloyls) were isolated from the red maple species
as previously reported [14, 15].

2.2 Measurements of α-glucosidase inhibitory assay.
A mixture of 50μL test samples and 100μL 0.1M phosphate buffer (pH 6.9)
containing yeast α-glucosidase solution (1.0 U/mL) were incubated in 96-well plates
at 25°C for 10minutes. After pre-incubation, 50μL of 5mM pnitrophenyl-α-Dglucopyranoside solution in 0.1M phosphate buffer (pH 6.9) were added to each well
at timed intervals. The reaction mixtures were incubated at 25°C for 5 minutes.
Before and after incubation, absorbance was recorded at 405nm by a micro-plate
reader (SpectraMax M2, Molecular Devices Corp., operated by SoftmaxPro v.4.6
software, Sunnyvale, CA) and compared to that of the control which had 50μL buffer
solutions in place of the samples. The α-glucosidase inhibitory activity was
expressed as inhibition % and was calculated as: Inhibition % = 100 × [(C5 – C0) –
(S0 – S0)] / (C5 – C0), where C0 is the absorbance of the reagent blank in 0 minute,
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S0 the absorbance of the samples in 0 minute, C5 the absorbance of the reagent blank
in 5 minutes, and S5 the absorbance of the samples in 5 minutes [22].

2.3 Kinetics of α-glucosidase inhibition.
The inhibition types of ginnalin A (GA), maplexin F (MF), and maplexins J (MJ)
were determined from Lineweaver–Burk plots, using previously reported methods
with minor modifications [23]. Typically, two concentrations around the IC50 values
of each sample were chosen (ranging from 2 – 250μM). For each concentration, αglucosidase activities were tested by using different concentrations of pPNP
glycoside (1 to 1000μM). The mixtures of the enzyme and the inhibitor were
dissolved in 50mM phosphate buffer (pH 6.8), and pre-incubated at room
temperature for 30 minutes, and then the substrate was added. The enzymatic
reaction was carried out at room temperature for 60 seconds, and monitored
spectrophotometrically by measuring the absorbance at 405nm. Inhibition types of
the inhibitors were determined by double-reciprocal plots.

2.4 Titration microcalorimetry.
Isothermal titration calorimetry (ITC), used to determine the thermodynamic
properties between the GCGs and α-glucosidase, were measured with a VP-ITC
Microcalorimeter (MicroCal, Northampton, MA, USA) according to previously
reported methods with modifications [24]. A typical titration experiment consisted
of 17 consecutive injections at 240s intervals consisting of 14μL injections of each
GCGs into the titration cell at 25°C in phosphate buffer (pH 7.0, 100mM). The
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titration cell was stirred continuously at 310 rpm. The GCGs (1-4mM) and αglucosidase enzyme (0.026-0.031mM) were dissolved in the same phosphate buffer
and degassed for 20 mins under vacuum using a ThermoVac (MicroCal,
Northampton, MA, USA) prior to each experiment. Controls included buffer
injected into buffer and GCGs injected into buffer solutions, respectively. Data was
analyzed by using nonlinear regression with a single-site binding model in VP
Viewer 2000, which uses the scientific plotting software, ORIGIN 7 (Origin Lab.
Corp., Northampton, MA, USA).

2.5 Hydrophobic interactions of α-glucosidase using bis-ANS.
α-glucosidase (2μM) was incubated in the presence of various concentrations of the
GCGs (0-80μM) at 37°C for 5 minutes. Bis-ANS (5μM) was then added, and
fluorescence was measured after incubation at 37°C for 15 minutes (λex = 400nm,
λem = 440−600 nm) [25].

2.6 Circular dichroism (CD) spectroscopy.
Far UV CD measurements (190-240nm) were conducted on a Jasco J-810
spectropolarimeter equipped with a Peltier temperature controller at 25°C. Briefly,
2μM of α-glucosidase was treated with various concentrations of the GCGs (080μM). The samples were dissolved in 200µL of a sodium phosphate buffer (0.1M,
pH 6.8) and placed in a 1.0mm path length cell. The spectra was collected and
corrected by subtraction of a blank 0.1M sodium phosphate buffer (pH 6.8), reducing
noise and smoothing [26]. The changes of secondary structure of α-glucosidase were
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estimated according to a method in the DichroWeb program, an online server for
protein secondary structure analyses from the CD spectroscopic
data [27, 28].

2.7 Homology modeling of α-glucosidase.
The Saccharomyces cerevisiae α-glucosidase was downloaded from the UniProt
protein knowledgebase (accession number P53341) [29]. The structure of isomaltase
from Saccharomyces cerevisiae (PDB entry 3A4A) that shared a 71.8% sequence
identity and 87.1% sequence similarity with Saccharomyces cerevisiae αglucosidase based on National Center for Biotechnology Information Basic Local
Alignment Search Tool (NCBI BLAST) search results was selected as the template
for homology modeling. Sequence alignment and structural model building were
performed using DS 3.5 (Discovery Studio, version 3.5, Accelrys, Inc., San Diego,
CA, USA). Ten initial 3D α-glucosidase structures were constructed and sorted in
ascending order of PDF total energy score. The best structure with the most negative
score was selected for further refinements.

2.8 Refinement of 3D α-glucosidase structure.
Molecular dynamics (MD) simulation is widely used for both homology and X-ray
structural refinement [30, 31]. The initial best 3D α-glucosidase structure from
homology modeling was refined through MD simulations using Amber12 [32]. The
initial structure was solvated in an octahedron periodic box (based on the TIP3P
model) with 12Å of water along each dimension. The protein was applied with the
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Amber ff99SB force field and counter-ions were added to the system to neutralize
charges [33].

MD simulations consisted of energy minimization, heat phase, equilibration, and
production. The solvated system was minimized by three steps. First, a harmonic
constraint potential of 10kcal/mol/Å2 was applied to all atoms except water
molecules. Second, the protein backbone atoms were restrained with a force of
5.0kcal/mol/Å2. Finally, all atoms were allowed to move freely. In each step, energy
minimization was executed by the steepest descent method for the first 2000 steps
and the conjugated gradient method for the subsequent 2000 steps. After
minimization, the system was gradually heated in the canonical “NVT ensemble”
from 0 to 300 Kelvin (K) in 100 picoseconds (ps) using a Langevin thermostat with
a coupling coefficient of 1.0ps with a force constant 10kcal/mol/Å2 on the protein.
The system was then equilibrated for the first two 500ps and subsequent three 200ps
at 300K with decreasing restraint weights reduced from 10 to 0.2kcal/mol/Å2. A
production simulation run for 10ns was lastly performed at 300K. During the MD
simulations, the long-range Coulombic interactions were handled using the particle
mesh Ewald (PME) method and the cutoff distance for the long-range van der Waals
(vdW) energy term was set at 10.0Å [34]. All hydrogen atoms were constrained
using the “SHAKE” algorithm and the time step was set at 2 femtosecond.
Coordinate trajectories were recorded every 2ps. The refined 3D α-glucosidase
structure was obtained from last snapshot of MD simulations and validated by
Profiles-3D Verify module in DS 3.5.
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2.9 Molecular docking.
GA, MF, and MJ were optimized using MMFF94s force field. The refined
αglucosidase structure from MD simulations was protonated based on amber99 force
field after removing water molecules. To obtain the most plausible binding sites, we
searched the whole 3-D space of the receptors, including both the active-site
(Asp214, Glu276 and Asp349) and non-active-site regions. Site Finder module
encoded in MOE (MOE 2010.10. Chemical Computing Group, Inc. Montreal,
Canada) was employed for detecting potential ligand binding sites of α-glucosidase.
MOE-docking was employed to identify the binding poses of GA, MF, MJ and αglucosidase. During docking study, 30 poses per compound were retained. All
docked poses of GA, MF, and MJ were ranked on the basis of the binding docking
energies according to London G score [35, 36]. The best conformation for each
compound from clustering results was chosen for binding mode analyses.
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3. Results
3.1 Comparison of α-glucosidase inhibitory effects of GCGs
As shown in Table 1, the inhibitory activities of the GCGs against the α-glucosidase
enzyme increased with increasing number of galloyl groups attached to the 1,5anhydro-D-glucitol moiety. The mono-galloyl substituted gallotannins (GB and
GC) did not demonstrate any inhibitory activities on α-glucosidase (IC50 > 1000μM),
and the di-galloyl gallotannin (GA) only showed a moderate inhibitory activity with
an IC50 value of 216.43μM. However, the activities of MF and MJ, which contain
three and four galloyl groups, respectively, were significantly enhanced (IC50 =
13.70 and 4.27μM, respectively). The results indicated that MF and MJ were potent
α-glucosidase inhibitors.

To further evaluate the inhibitory characteristics of GA, MF and MJ, enzyme kinetic
assays were performed and their inhibition types were determined by the
Lineweaver-Burk plots (Figure 3). The Lineweaver-Burk plot of each GCG (at
different concentrations ranging from 2 – 250μM) generated straight lines that all
intersected the X-axis at the same point, suggesting that the GCGs were typical
noncompetitive inhibitors of α-glucosidase. Therefore, this implied that GA, MF,
and MJ bind to the noncompetitive site of the yeast’s α-glucosidase enzyme rather
than to the catalytic domain of the enzyme.
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3.2 ITC measurement
The thermodynamic properties of the binding interaction between the GCGs and αglucosidase complex were determined by using ITC. The titration peaks of GA, GB,
and GC (at concentrations ranging from 1-4mM) were too weak to yield
thermodynamic parameters. However, the titration peaks for MF or MJ
(concentrations ranging from 1-2mM) showed binding interactions that were
typically exothermic (see Figure 3). The thermodynamic parameters for GA, MF,
and MJ, obtained from the ITC analyses, are summarized in Table 2. Both MF and
MJ had a ligand:enzyme ratio (N value) of 1:1 indicating that one molecule of each
of these GCGs binds to one molecule of the enzyme [37]. In addition, the binding
constants (Ka) of MF or MJ with α-glucosidase were 2.85 x 104 and 4.22 x 104 mol1, respectively. The stronger binding affinity of MJ with α-glucosidase, compared to
that of MF and the enzyme, was in agreement with the results obtained from the αglucosidase inhibitory assay with these GCGs (Table 1) [38]. The negative ΔG
values for both MF and MJ (-6.09 and -6.31kcal/mol, respectively) suggested that
their binding interactions were spontaneous [38, 39]. Furthermore, a positive ΔS
value and a negative ΔH value for both MF and MJ indicated that their binding
interactions with the α-glucosidase enzyme were enthalpy-driven [39, 40]. Notably,
the thermodynamic parameters observed for MF and MJ are similar to those reported
for the major gallotannin present in tea, namely, epigallocatechin gallate (EGCG),
with lipase [38].
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Given that a positive ΔS value may be associated with the first stage of binding
interaction, [41, 42] where the ligand and enzyme are immobilized in a hydrophobic
environment, we further examined the hydrophobic alteration of the α-glucosidase
enzyme.

3.3 GCGs reduced the hydrophobicity of α-glucosidase.
Noncovalent fluorescent probes have been extensively used for the study of protein
conformation [43, 44]. An external fluorescent probe such as bis-8anilinonaphthalene-1-sulfonate

(bis-ANS)

is

sensitive

to

the

protein

microenvironment and selectively binds to the hydrophobic surface of protein [45].
Therefore, a bis-ANS probe was utilized to assess the exposure of α-glucosidase
hydrophobic surface induced by the ligands. As shown in Figure 4, after being coincubated with α-glucosidase for 20min at 37°C, GA, MF, and MJ were able to
decrease the fluorescence of the bis-ANS-enzyme complex in a concentrationdependent manner. Although GA slightly decreased the fluorescent intensity of the
bis-ANS-enzyme complex at the low concentration (20μM), compared to the nontreatment group, the fluorescence of the MF and MJ treatment groups were
significantly reduced. Moreover, all three ligands greatly decreased the fluorescence
at concentration of 80μM, suggesting that GA, MF, and MJ could decrease the
hydrophobic surfaces of α-glucosidase.
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Since hydrophobic surface is crucial to facilitate the formation of the enzyme active
site, GA, MF, and MJ could have possibly inhibited the α-glucosidase enzyme
activity by inducing poor hydrophobic surfaces on the enzyme structure [46].

3.4 Change in conformation of α-glucosidase induced by GCGs.
To further examine the effects of the GCGs on the secondary structure of αglucosidase, circular dichroism (CD) spectra of free αglucosidase and ligand-αglucosidase complex were acquired. In Figure 5, the CD spectra of the free αglucosidase enzyme exhibited two characteristic negative bands at 208 and 222nm,
indicating that the major secondary protein structure presented in the α-glucosidase
was αhelix [47, 48]. When various concentrations (20-80μM) of the GCGs were coincubated with αglucosidase, the CD spectra of the ligand-enzyme complex was
significantly altered indicating that the conformation of the enzyme protein was
affected by the ligands in a concentration dependent manner. As summarized in
Table 3, the GCGs bind to the enzyme protein that mainly resulted in the loss of αhelix conformation. When 40μM of MF and MJ were delivered to α-glucosidase,
the enzyme lost 4.9 and 5.6% of its α-helix conformation, respectively, which could
potentially cause the loss of biological functions of the α-glucosidase enzyme.

3.5 Homology modeling.
Lacking the 3D structure of Saccharomyces cerevisiae α-glucosidase used in
biological assays, we constructed a 3D homology structure of α-glucosidase by
computational approach. The 3D homology models of α-glucosidase were generated
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with the MODELER module in DS 3.5, and the best model with lowest PDF total
energy score was refined by 10ns MD simulations (Figure 6B). Trajectory-based
analysis showed that the root-mean-square deviation (RMSD) of the protein
backbone atoms with reference to the initial structural coordinates increased slowly
in the first 4 nanoseconds (ns) and then subsequently stabilized after 4 ns, suggesting
that the α-glucosidase structure was stable.

The refined structure from the last snapshot of MD simulations was validated via
Profile-3D, Procheck, and Prostat analysis. The overall self-compatibility score
generated by Profile-3D module in DS 3.5 for this refined model was 252.5 (the
verified expected high score was 263.47, and the verified expected low score was
118.56). Procheck was used to calculate the φ and ψ angles (Figure 6A) and four
residues (Ser331, Glu522, Arg543, and Tyr372) were located in un-allowed regions,
and the percentage of residues within the Ramachandran plot’s allowed regions was
99.32%. Prostat analysis showed that almost all bond lengths, angles, and torsions
stayed within a rational range. All of these validation results proved that the refined
model is reliable.

3.6 Binding modes analyses.
A total of 35 potential ligand binding sites of the refined model were obtained from
Site Finder module in MOE. The largest five binding sites (size>100) were selected
for the docking study (Figure 6). As shown in Table 4, the three GCGs, namely, GA,
MF, and MJ, shared the same scaffold, suggesting that they bind at the same site for
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a given target. Sites 2, 4, and 5 were not suitable for these compounds because the
trends of the docking scores for GA, MF, and MJ were inconsistent with the
corresponding enzyme assay results. For example, compound MF in binding site 4
with a docking score of -17.37Kcal/mol is lower than that of compound MJ (15.03Kcal/mol) which is inconsistent with their enzyme inhibition values (13.70μM
for MF and 4.27tμM for MJ). Similar trends were observed in the docking results of
binding sites 2 and 5.

As shown in Figure 7C, binding site 3 was located at two helix structures and the
three GCGs showed considerable binding modes based on the docking score and the
enzyme inhibition assay. As previous studies have suggested that the helix structure
could be stabilized by targeting compounds with polyhydroxyl groups, [21, 23, 49]
our CD results suggest that the helix structures were reduced with increasing
concentrations of GA, MF, and MJ. Therefore, this implied that binding site 3 is not
targeted by these GCGs.

Binding site 1 is surrounded by coil, bend, and sheet structures, with little helix
structures, which contain both active and inactive sites (Figure 7A). The trends of
docking score of GA, MF, MJ, and the enzyme assay results are consistent. Based
on all of the above analyses, the GCGs, GA, MF, and MJ target the binding site 1 of
Saccharomyces cerevisiae α-glucosidase. The active site of α-glucosidase is
comprised of Asp214, Glu276 and Asp349 and is represented by the red oval in
Figure 8D. Superimposition of the binding modes of GA, MF, and MJ suggested
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that all of the binding sites are located at the noncompetitive domain of αglucosidase (Figure 8A, B, and C), which are relatively close to the active site
(Figure 8D). All of the docking results demonstrate that GA, MF, and MJ are
noncompetitive inhibitors, in accordance with the aforementioned kinetic results
(Figure 2).

As shown in figure 8A, the hydroxyl group of GA can form two hydrogen bonds
with the side chain of Ser244 and Phe157. One galloyl group of GA is inserted in
the polar area comprised of Arg312, Glu304, Arg439, and Gln350, suggesting that
a polar interaction can be formed. Moreover, the phenyl group can form favorable
hydrophobic interactions with the side chains of Phe158, Phe157, His239, and
His279. Compounds MF and MJ contain more galloyl groups than GA, suggesting
that more favorable binding interactions will be formed against a given target
according to Ge and coworkers’ results [50]. As shown in figures 8B and 8C, MF
can form four hydrogen bonds with Asp408, Glu304, Ser244, and Phe157, whereas
MJ can form eight hydrogen bonds with Glu304, Ser244, Ser299, Glu276, Arg212,
Thr215, and Ala216. Thus, hydrogen bonds are formed via the hydroxyl groups of
these GCGs. Notably, a similar phenomenon has been observed in other phenolic
compounds such as xanthone derivatives [23], resveratrol, and oxyresveratrol [21].
Moreover, more favorable hydrophobic interactions are formed between MF and MJ
and α-glucosidase residues (Phe157, Phe158, Leu237, His239, His279, Phe300, and
Ala278 for MF, and Phe157, Pro309, Leu237, His239, Leu218, His279, and Arg312
for MJ). These hydrophobic sites were occupied by GCGs, suggesting that the GCGs
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decreased the hydrophobic surface of the enzyme which was consistent with the data
obtained from the bis-ANS assay. Also, the binding energy of GA, MF, and MJ is 10.45, -13.02, and -16.35kcal/mol, respectively, which was in full accordance with
results from the enzyme inhibition assay and binding model analyses.
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4. Discussion
The red maple (Acer rubrum) species is endemic to eastern North America and
widely known for its tree sap which is used to produce the natural sweetener, maple
syrup. This plant has also been used by the Native Americans as an herbal medicine,
and recent phytochemical and biological studies from our group on this species led
to the discovery of several GCGs [14-16]. More importantly, these GCGs show
potential as natural AGIs based on in vitro and animal studies [14-16, 18]. While
several of these GCGs showed far more potent α-glucosidase inhibitory activities
than the clinical drug, acarbose, their mechanisms of action remained unknown.
Herein, we reveal several key mechanisms by which these GCGs interact with αglucosidase.

First, the inhibition type of the GCGs against the α-glucosidase enzyme was found
to be noncompetitive, suggesting that these gallotannins bind to the specific site of
enzyme-substrate complex rather than the enzyme catalytic domain. This binding
pattern is in agreement with previous studies of a ‘glucose-core containing
gallotannin’, namely, pentagalloyl glucose (PGG), which is also a noncompetitive
α-glucosidase inhibitor [51]. It is noteworthy that this distinguishes the GCGs from
acarbose, a synthetic AGI, which is known to be a competitive inhibitor that directly
binds to the active site of α-glucosidase [52]. In addition, increasing the number of
galloyl groups on the glucitol core enhanced the α-glucosidase inhibitory activities
of these GCGs, an SAR effect that has also been observed in glucose-core containing
gallotannin α-glucosidase inhibitors, namely, PGG and its analogs [51].
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Second, ITC analyses revealed that the binding stoichiometry between the GCGs
(MF and MJ) and α-glucosidase was in a 1:1 ratio suggesting a single binding site
for these compounds. This data is similar to that reported for the tea gallotannin,
epigallocatechin gallate (EGCG) and lipase [38]. Additionally, the thermodynamic
parameters (Table 2) revealed that the formation of the ligand-enzyme complex was
spontaneous and enthalpy-driven suggesting that the binding interaction was largely
attributed to the hydrogen bonding. This is not surprising since it has been well
established that gallotannins form hydrogen bonds with the polar residues of proteins
through their galloyl and/or hydroxyl groups [53, 54]. This observation was further
supported by our computational models. Given that gallotannins-protein binding
can be enthalpy-driven (by hydrogen bonding and protonation) [55-57], entropic
factors (such as hydrophobic interactions) [41], are also often involved in the
formation of ligand-protein complexes. Therefore, we examined the hydrophobicity
of the GCGs and α-glucosidase complex.

The GCGs reduced the hydrophobic surface of the enzyme and impeded the
formation of the active center of the α-glucosidase enzyme. GA, MF, and MJ
significantly decreased the α-helix conformation of the enzyme protein. Since αhelix is a rigid secondary structure that maintains many enzymatic protein functions,
loss of this structure may result in enzyme destabilization. Therefore, the major
inhibitory mechanism of the GCGs against α-glucosidase mainly consists of binding
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to the enzyme-substrate complex, reducing the hydrophobic surface, and changing
the α-helix conformation of the enzyme protein.

Lastly, the GCGs act as noncompetitive inhibitors that bind to a noncompetitive
domain of α-glucosidase located at relatively close to the active site (Figure 7D).
This noncompetitive domain is different from the binding pocket of acarbose
(competitive inhibitor) [52]. The predicted noncompetitive binding site may provide
a novel site for structure-based discovering and designing novel α-glucosidase
inhibitors. The molecular docking results demonstrate that more galloyl groups in
the GCGs leads to enhanced binding affinity against α-glucosidase. However,
further in silico studies to investigate the dynamic mechanisms of whether GCGs
could trigger the loss of the secondary α-helix of the flexible structures (binding sites
of GCGs) is warranted and included in our group’s future studies.

Therefore, overall, this study provides useful information on these GCGs which can
be used to guide the design of new GCG analogs with superior activities against αglucosidase.
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5. Conclusion
In summary, we have determined the inhibition type of ‘glucitol-core containing
gallotannins (GCGs)’. The ligand-enzyme interaction was studied using several
biophysical and spectroscopic tools including ITC, fluorescent probe and CD
spectra. Our results showed that these GCGs had a single binding site, they could
decrease the hydrophobic surfaces of the enzyme protein, and also reduce the α-helix
conformation content of the protein’s secondary structure. Our study provides
valuable information underlying the interactions between these GCGs and αglucosidase, a crucial step towards further investigating their potential as natural
AGIs. Further investigation of these GCGs will focus on in vivo studies to evaluate
their safety and efficacy as potential dietary agents for T2DM management which is
included in our group’s future planned studies.
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Table 1: α-Glucosidase inhibitory activities of GCGs
Compound

# of galloyl group

IC50 (μM) a

Type of inhibition

ginnalin B (GB)

1

> 1000

n.d.

ginnalin C (GC)

1

> 1000

n.d.

ginnalin A (GA)

2

216.4 ± 3.19

noncompetitive

maplexin F (MF)

3

13.70 ± 0.87

noncompetitive

maplexin J (MJ)

4

4.270 ± 0.13

noncompetitive

─

142.4 ± 1.68

competitive

acarbose

b

a

IC50 values are shown as mean ± S.D. from three independent experiments;
b

Positive control; n.d. = not determined.
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Table 2: Thermodynamic parameters for GCGs [ginnalin A (GA); maplexin F
(MF) and maplexin J (MJ)] binding to α-glucosidase enzyme

Ligand N [GCGs/αglucosidase]
GA
n.d.

Ka[104 mol-1] ΔG [kJ mol-1] ΔH [kJ mol-1] ΔS [J mol-1 K-1]
n.d.

n.d.

n.d.

n.d.

MF

1.01

2.85

-6.09

-10.26

14.06

MJ

1.01

4.22

-6.31

-25.17

63.31

n.d.: not detected
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Table 3: The effect of GCGs (GA, MF, and MJ) on the secondary structure of αglucosidase enzyme
Ligands (Conc.) α-Helix % β-Fold % β-Turns % Unordered
Control

36.3

21.9

14.3

26.9

GA 40μM

37.8

22.7

11.5

27.8

GA 80μM

33.5

22.5

15.8

27.7

MF 20μM

30.7

24.7

15.6

28.4

MF 40μM

31.2

22.7

16.6

28.9

MJ 20μM

31.8

21.1

20.4

26.4

MJ 40μM

30.7

24.4

19.1

25.3
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Table 4: Detailed docking results for GA, MF, and MJ. Cluster represents the
docking score of the lowest binding energy conformation of the more populated
cluster.
compound
GA
MF
MJ
Site 1

Range
cluster

(-17.59, -8.53)
-10.54

(-19.87, -11.98)
-12.02

(-21.70, -9.40)
-16.53

Site 2

Range
cluster

(-12.57, -5.78)
-8.44

(-12.56, -6.80)
-8.15

(-13.77, -6.39)
-9.14

Site 3

Range
cluster

(-16.11, -6.47)
-11.27

(-18.20, -8.70)
-12.25

(-19.47, -7.70)
-13.04

Site 4

Range
cluster

(-14.41, -5.28)
-10.26

(-17.37, -6.43)
-10.37

(-15.03, -5.90)
-9.86

Site 5

Range
cluster

(-15.24, -7.46)
-11.32

(-17.78, -6.23)
-11.72

(-16.00, -7.53)
-11.06
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Figure 1: Chemical structures of five ‘glucitol core containing gallotannins
(GCGs)’: ginnalin A, ginnalin B, ginnalin C, maplexin F and maplexin J.
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Figure 2: Lineweaver-Burk plots of the kinetics of inhibition of GA (A), MF (B)
and MJ (C) on α-glucosidase enzyme. Two concentrations (ranging from 2 250μM of ligands; close to their IC50 values) were co-incubated with α-glucosidase
at 37°C for 30min, then pNPG was added at varying concentrations (from 11000μM).
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Figure 3: Results of isothermal titration calorimetry (ITC) for GCGs binding to αglucosidase: (Top) Raw data plot of heat flow against time for the titration of MF (A)
or MJ (B) into 0.031mM α-glucosidase enzyme protein. (Bottom) Plot of molar
enthalpy change against GCGs/αglucosidase enzyme molar ratio.
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Figure 4: Fluorescence intensity of bis-ANS-α-glucosidase complex. The changes
of fluorescence intensity were induced by GA (A), MF (B) and MJ (C) at different
concentrations ranging from 20 – 80μM.
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Figure 5: Circular dichroism (CD) spectra of the α-glucosidase-GCG complex. αglucosidase (2μM ) were co-incubated with GA, MF, or MJ at 20-80μM at 37°C
for 20 min.
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Figure 6: The properties of the refined α-glucosidase structure. (A) Ramachandran
plot for a 3D model of α-glucosidase (residues denoted with a + are outliers); (B)
Time dependences of the root mean square deviations (RMSD) of the backbone
atoms (Cα, N, O-atoms) with respect to initial structure.

105

Figure 7: Top five potential ligand binding site generated via Site Finder module in
MOE2010.10. The binding site is represented by alpha sphere centers and red oval.
The active site is comprised of catalytic residues (Asp 214, Glu276, and Asp349).
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Figure 8: Binding modes for GA (A), MF (B), MJ (C), and superimposition of the
binding modes of GA (red), MF (aquamarine blue), and MJ (blue). Hydrogen
bonds are depicted by red dotted lines. Red oval represents the active binding site.
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Synthesis of tetragalloylglucitol (maplexin J)
The tetragalloylglucitol gallotannin (assigned the common name of maplexin J (MJ))
was synthesized by modification of the previously published method as shown in
Scheme 1 [19]. Briefly, gallic acid (i, 101mg, 0.6mmol) was dissolved in dry N,Ndimethylformamide (DMF, 2mL). Imidazole (513mg, 7.5mmol) and tertbutyldimethylsilyl chloride (TBDMS, 521mg, 3.5mmol) were added to the solution
and stirred at room temperature under nitrogen atmosphere for 24 hours. A white
crystalline product precipitated out of the reaction solution. Trisilyl-protected gallic
acid (ii) was isolated (244mg, 82%) from the precipitant using silica gel column
chromatography.
Compound ii (187mg, 0.4mmol) and glucitol (iii, 10.4mg, 0.06mmol) were
dissolved in dry dichloromethane (DCM, 2mL). N, N'-diisopropylcarbodiimide
(DIC, 61.4mg, 0.5mmol) was added followed by 4-dimethylaminopyridine (DMAP,
74.4mg, 0.06mmol). The mixture was stirred at room temperature under nitrogen
atmosphere for 96 hours. The crude product was purified using silica gel column
chromatography to yield compound iv.
Compound iv (843mg, 64.6%) was isolated and its structure was confirmed by 2D
NMR heteronuclear multiple bond correlations (HMBC) from the three sugar
methines and the sugar methylene to the respective carbonyl carbons of the gallic
acids. Deprotection of compound iv was accomplished in the presence of tetra-nbutylammonium fluoride (TBAF). Compound iv (50mg, 0.023mmol) was dissolved
in dry tetrahydrofuran (THF, 2mL). TBAF (61.1mg, 0.23mmol) was added, and the
mixture was stirred at room temperature under a nitrogen atmosphere for 10 minutes.
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The crude product was purified using reverse-phase high-pressure liquid
chromatography (HPLC) to yield the final product (10mg, 52.3%), which was
characterized as tetragalloylglucitol and assigned the common name of maplexin J
(MJ) based on its nuclear magnetic resonance (NMR) spectroscopic data (Table 1;
key HMBC correlations shown in Figure 1). This scheme was carried out several
times to synthesize enough maplexin J for further biological assays, fortunately
maplexin E, a tri-galloylglucitol, was isolated and elucidated as an additional side
product.
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Scheme 1: Synthetic scheme of maplexin J.
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Table 1. The 1H and 13C NMR data of maplexin J. Data was measured in CH3OD
at 500 MHz (1H) and 125 MHz (13C).

δC

No.
Glucitol Sugar Core
1

66.6

2
3
4
5
6

69.6
73.8
68.9
76.7
62.3

Galloyl A
1a
2a, 6a
3a, 5a
4a
7a
Galloyl B 1b

118.9
108.9
145.1
138.8
165.8

2b, 6b
3b, 5b
4b
7b
Galloyl C
1c
2c. 6c
3c, 5c
4c
7c
Galloyl D
1d
2d, 6d
3d, 5d
4d
7d

119.2
108.9
144.8
138.6
166.2
118.9
109.0
145.0
138.8
165.6
119.7
108.8
145.0
138.5
166.6
111

δH (mult, J in Hz)
4.20 (m)
3.54 (t, 11.1, 12.2)
5.19 (ddd)
5.65 (t, 9.9, 11.1)
5.39 (t, 9.9, 10.7)
3.94 (m)
4.36 (d, 12.1)
4.19 (m)

6.88 (2H, s)

6.82 (2H, s)

6.87 (2H, s)

7.00 (2H, s)

Figure 1. Key HMBC correlations of maplexin J.
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ABSTRACT
Previous reports have demonstrated the ability of pomegranate extract (PE) and
pomegranate juice (PJ) to attenuate Alzheimer’s disease (AD) pathogenesis in several
transgenic animal models, as well as aiding in memory related tasks in humans [1-4].
Collectively, these findings suggest a role for pomegranate to augment memory
function through task-related activities. The pomegranate fruit is a rich source of
ellagitannins, most notably punicalagin. However, upon ingestion, ellagintannins are
poorly absorbed in the gut and are quickly hydrolyzed releasing their hallmark
‘hexahydroxydiphenyl’ substituent, which quickly undergoes an internal lactonization
to generate ellagic acid. Unfortunately, much like its parent compound, ellagic acid is
not readily absorbed and does not reach physiologically relevant plasma
concentrations. Ellagic acid is metabolized by the gut microflora into dibenzopyranone
derivatives, known as urolithins. The urolithins, most notably urolithin A (UA; 3,8dihydroxy-6H-dibenzo(b,d)pyran-6-one)

achieves

biologically

significant

concentrations (20-100µM) in plasma and select tissues [5-7]. As ellagitannins are the
major class of compounds found in pomegranate, we therefore hypothesize that the
urolithins could be the neurologically active compounds responsible for the link
between pomegranate and AD.

Our first priority was to synthesize several of the most physiologically relevant
urolithin derivatives including urolithin A (3,8-dihydroxybenzo[b,d]pyran-6-one),
methyl-urolithin A (3-methoxy-8-hydroxybenzo[b,d]pyran-6-one), urolithin B (3hydroxy-6H-dibenzo[b,d]pyran-6-one) and methyl-urolithin B (3-methoxy-6H-
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dibenzo[b,d]pyran-6-one). Using these synthetic standards, LC-MS/MS methods have
been developed in conjunction with cellular, tissue, and Caenorhabditis elegans,
uptake studies.
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Abstract
Pomegranate shows neuroprotective effects against Alzheimer’s disease (AD) in
several reported animal studies. However, whether its constituent ellagitannins and/or
their physiologically relevant gut microbiota-derived metabolites, namely, urolithins
(6Hdibenzo[b,d]pyran-6-one derivatives), are the responsible bioactive constituents is
unknown. Therefore, from a pomegranate extract (PE), previously reported by our
group to have anti-AD effects in vivo, 21 constituents, which were primarily
ellagitannins, were isolated and identified (by HPLC, NMR, and HRESIMS). In silico
computational studies, used to predict blood-brain barrier permeability, revealed that
none of the PE constituents, but the urolithins, fulfilled criteria required for penetration.
Urolithins prevented β-amyloid fibrillation in vitro and methyl-urolithin B (8-methoxy6H-dibenzo[b,d]pyran-6-one), but not PE or its predominant ellagitannins, had a
protective effect in Caenorhabditis elegans post induction of amyloid β1−42 induced
neurotoxicity and paralysis. Therefore, urolithins are the possible brain absorbable
compounds which contribute to pomegranate’s anti-AD effects warranting further in
vivo studies
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1. Introduction
Alzheimer’s disease (AD) is a degenerative brain disease that is projected to affect over
115 million people worldwide by 2050. AD is a leading cause of disability and
morbidity among patients and is among the most costly chronic diseases known to
society. Apart from its public health burden, the economic cost of AD exceeded 200
billion dollars for 2014 alone which is estimated to increase 5-fold by 2050 [1]. If the
incidence of AD continues on its current trajectory, it will cripple the health care
systems of several countries including the United States where it is the sixth leading
cause of death [2]. Unfortunately, despite several decades of research, many approved
drugs for AD have little effect on slowing disease progression. In fact, it is estimated
that the brain changes for AD may begin more than 20 years before symptoms of the
disease appear and it is often too late to reverse AD pathology by the time of diagnosis.
Therefore, it is imperative that other approaches, such as the utilization of natural
products as dietary intervention strategies, be explored as preventive and/or diseasemodifying measures to slow or stop AD progression.

Among natural compounds, plant polyphenols have emerged as an important
nonpharmacologic approach for AD prevention and treatment [3,4]. However, the
majority of polyphenols, including the subclass known as ellagitannins, are poorly
absorbed in the small intestine and do not achieve physiologically relevant
concentrations in circulation [5,6]. Instead, they reach the colon where they are
extensively metabolized by gut microbiota to colonic-derived metabolites, which are
implicated with a vast array of biological effects [7,8]. Given considerable inter118

individual variability in microflora, and different phenotypes being observed with
“metabolite-producers and non-producers” after consumption of many polyphenol
subclasses, including ellagitannins [9]. Further investigations into understanding the
biological effects of these colonic metabolites are necessary.

The pomegranate (Punica granatum L.) fruit is a rich source of ellagitannins, primarily
punicalagin (PA) and its hydrolysis product, ellagic acid (EA) [10]. Pomegranate juice
and extracts have been reported to show neuroprotective effects against AD
pathogenesis in several transgenic animal models but the bioactive compound/s
responsible have not been characterized [11−14]. Furthermore, the identity of the brain
absorbable compounds, whether they are the natural ellagitannin constituents present
in pomegranate, and/or their in vivo colonic-derived metabolites, is not known.

The bioavailability and metabolism of ellagitannins in human subjects, after the
consumption of pomegranate juice and pomegranate extracts, are well established [56]. The major pomegranate ellagitannins, PA and others, are not found intact in
circulation, but rather are hydrolyzed to release EA and then subsequently
biotransformed by gut microbiota to yield urolithins (6H-dibenzo[b,d]pyran-6-one
derivatives) (see Figure 1A). These urolithins and their phase-2 enzyme conjugates
[methylated (i.e., conversion of hydroxyl to methoxyl or methyl ether), sulfated, and
glucuronidated forms] [15] achieve physiologically relevant concentrations through
enterohepatic recirculation and persist in vivo following the regular consumption of
pomegranate foods [5−8]. Therefore, the poor bioavailability and extensive metabolism
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of pomegranate ellagitannins to urolithins suggest that these latter metabolites may be
relevant bioactive compounds in vivo [5]. Moreover, urolithins have been reported to
show anti-inflammatory [5], and anti-glycative and neuroprotective effects in vitro
[16]. However, it is also possible that there are unidentified compounds, yet to be
isolated from pomegranate, which are responsible for its neuroprotective effects.

Our group has recently reported on the biological effects of an ellagitannin-enriched
pomegranate extract (PE) in an aged AD transgenic animal model [17]. Therefore, from
this PE, herein we sought to (1) isolate and identify its chemical constituents; (2)
conduct in silico computational studies to evaluate whether the PE constituents and
several urolithin analogues [urolithin A (UA) and urolithin B (UB) and their methyl
derivatives, mUA, and mUB, respectively], can cross the blood-brain barrier (BBB);
(3) evaluate the in vitro effects of PE, its constituents [PA, EA, and gallic acid (GA)],
and the urolithins, on Aβ1−42 fibrillation and; (4) evaluate the in vivo ability of PE and
the aforementioned pure compounds (constituents and urolithins) to abrogate Aβ1−42
induced neurotoxicity and paralysis in Caenorhabditis elegans. This is the first study
to investigate a PE, its constituents, and the urolithins, for in silico BBB penetrability
and in vitro and in vivo anti-AD potential.

Given that the PE was previously reported to show anti-AD effects in an animal model
[17], we first sought to isolate and identify all of its constituents. Twenty-one
compounds (see Figure 1B), predominantly ellagitannins, were identified from the PE
(by HPLC, NMR, and mass spectral data; described in the Supporting Information).
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The isolates included PA, EA, and gallic acid (GA) and other compounds common to
pomegranate [10, 18]. In addition, a new ellagitannin was isolated and assigned the
common name of pomellatannin (1). This compound is a dehydroellagitannin acetone
condensate, and its structure is in accordance to similar ellagitannin-acetone derivatives
previously reported [19]. The remaining isolates 2−17 were identified based on 1H
NMR and/or
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C NMR data and by comparison of these data to published literature

reports as follows: punigluconin (2) [20], 6-O-galloyl-D-glucose (3) [21], gemin D (4)
[22], hippomanin A (5) [22], praecoxin B (6) [23], pedunculagin (7) [24], 1,6-di-Ogalloyl-β-D-glucose (8) [21], gallic acid-3-O-β-D-(6′-O-galloyl)-glucopyranoside (9)
[21], isocorilagin (10) [25], casuariin (11) [26], ellagic acid-4-O-β-D-glucopyranose
(12) [27], 3,3′-di-O-methyl-ellagic acid-4-O-β-D-glucopyranose (13) [28], 4-O-α-Lrhamnopyranosyl-ellagic acid (14) [29], 4-O-α-Larabinofuranosyl-ellagic acid (15)
[30], gallocatechin (16) [31], and brevifolincarboxylic acid (17) [32].

Having obtained the structures of the natural constituents present in the PE, which were
primarily ellagitannins, we next sought to investigate whether the isolates and their
colonic derived microbial metabolites, namely urolithins, could potentially cross the
BBB. Therefore, using in silico computational methods as previously reported [33], the
21 constituents identified in PE, as well as UA, UB, mUA, and mUB, were evaluated
for BBB penetrability. Interestingly, none of the isolates, but all of the urolithins,
fulfilled criteria required for BBB penetration (Table 1).
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The methyl derivatives of UA and UB (i.e., mUA and mUB) may have in vivo relevance
since these compounds could be formed from the metabolism of UA and UB by phenolO-methyltransferase, a mammalian enzyme which is highly localized in the liver, and
can transfer the methyl group of S-adenosylmethionine to phenols [34]. Indeed, mUA
has previously been detected in tissues of mice after oral delivery of UA [35]. However,
apart from these methyl derivatives, we also evaluated other potential mammalian
enzyme-biotransformation products, namely, sulfated and glucuronidated derivatives
of UA and UB for BBB penetrability. Interestingly, while none of these latter
metabolites fulfilled criteria required for BBB penetration, the dimethyl derivative of
UA (3, 8-dimethoxy-6H-dibenzo[b,d]pyran-6-one) did fulfill the criteria required for
BBB penetration (data not shown). Therefore, it is possible that the increased
lipophilicity caused by methylation of the hydroxyl group/s on UA and UB (to yield
the methyl ether/methoxyl derivatives) increases BBB penetrability unlike increased
hydrophilicity which is imparted by sulfation or glucuronidation. Methylated
conjugates of other polyphenols, including monomeric flavanols (catechins), have been
reported to remain intact and persist in vivo since they are not susceptible to enzymatic
deconjugation unlike sulfated and glucuronidated metabolites which can be
deconjugated in vivo by sulfatases and β-glucuronidases, respectively [36].

Apart from the dietary relevance of the urolithins and their conjugates due to their
formation from ellagitannins by colonic microbiota, their subsequent biotransformation
by mammalian enzymes, and their persistence in vivo through enterohepatic circulation
[5−8], they could also be explored for pharmaceutical potential given that structural
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analogues, and accompanying SAR (structure−activity related) studies, can yield
compounds with enhanced activity and BBB penetrability.

It is necessary, though, that the in silico data reported herein be substantiated by future
animal brain tissue disposition studies. Interestingly, a recent report (using mass
spectroscopic methods) has detected UB in brain tissues of rats after intravenous
delivery [37]. However, animal studies to evaluate brain deposition after repeated oral
exposure of PE, as well as the individual urolithin analogs, is warranted. These studies
are necessary since it has been reported that the brain bioavailability of certain
polyphenols, such as monomeric flavanols (catechins), can increase after repeated oral
dosing as has been observed with a polyphenol-rich grape seed extract [38]. Next,
biophysical methods were used to evaluate the effects of PE, its constituents (PA, EA,
and GA), and the urolithins on Aβ fibrillation. This is because elevated levels of Aβ
fibrillation and oligomerization in brain are associated with neurotoxicity in AD and
are characteristic hallmarks which play significant roles in both early and late stages of
AD [39, 40]. Therefore, agents which target the formation of Aβ fibrils and oligomers
could serve as therapeutic approaches for AD prevention and/or treatment. Aβ1−42
fibrillation was confirmed by the ThT assay which showed a significant increase in
fluorescence which was then correlated to binding levels of ThT to Aβ fibril content,
β-sheet formation [40] and peptide oligomerization [39]. The PE treated samples
reduced Aβ fibrillation by 35.9% and 76.4%, at 10 and 100 μg/mL, respectively. The
purified PE constituents and urolithins reduced Aβ fibrillation at levels ranging
6.5−65.4% (at 10μM) and 20.2−76.3% (at 100μM) (Figure 2). These inhibitory levels

123

were similar to those of resveratrol (37.6% at 10 μM and 74.4% at 100 μM), the wellknown grape/red wine polyphenol, which has also been previously reported to reduce
Aβ fibrillation in vitro [41]. Therefore, the preventive abilities of the urolithins on the
assembly of neurotoxic Aβ fibril structures may contribute to the overall
neuroprotective effect reported for pomegranate but further studies would be required
to confirm this.

Lastly, the PE was evaluated, its purified constituents, and the urolithins (all at 10
μg/mL), using an in vivo C. elegans model of AD. The mobility curves for the CL4176
C. elegans strain after the Aβ1−42 induction of muscular paralysis at 25°C are shown in
figure 3 and the mean, maximum, and median survival of the worms post heat shock
are shown in table 2. Compared to the control worms, treatment with PE (Figure 3B)
did not have any significant effect on the mean, maximum, or median survival/mobility
in C. elegans post induction of Aβ1−42 induced neurotoxicity and paralysis. Treatment
with EA (Figure 3D), UB (Figure 3F), mUA (Figure 3G), and GA (Figure 3I) did not
have any effect on the mean or medium survival/mobility in C. elegans but significantly
(p < 0.0001) increased the maximum survival/mobility by 10.6, 8.5, 12.6, and 16.4%,
respectively (Table 2). Among all of the samples, only treatment with mUB (Figure
3H) significantly (p < 0.0001) increased mean, maximum, and median
survival/mobility in C. elegans post induction of Aβ1−42 induced neurotoxicity and
paralysis by 5.6, 13.0, and 10.3% respectively (Table 2). Treatment with PA (Figure
3C) and UA (Figure 3E) did not have any significant effect on the maximum or median
survival/ mobility, but significantly (p < 0.0001) decreased the mean survival/mobility
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in C. elegans post induction of amyloid β1−42 induced neurotoxicity and paralysis by
5.6% (Table 2).

The uptake of urolithins, specifically UA and UB, has previously been reported in
different cell lines [42, 43], but to date, similar studies have not been conducted with
C. elegans. Therefore, using a protocol reported for C. elegans uptake studies with the
polyphenol, quercetin [44], wild type N2 nematodes were exposed to UA and
subsequent liquid chromatography mass spectroscopy (LC-MS/MS) analyses revealed
its uptake into the tissues of the worms. However, further quantitative and metabolism
studies of urolithins in C. elegans are warranted.

In summary, we isolated and identified the naturally occurring constituents present in
a PE previously reported to have anti-AD effects in an animal model [17]. None of
these compounds, but urolithins (gut microbial metabolites derived from ellagitannins),
fulfilled in silico criteria required for BBB penetration. Moreover, the urolithins
prevented β-amyloid fibrillation in vitro and methyl-urolithin B, but not PE or its
constituents, protected C. elegans post induction of Aβ1−42 induced neurotoxicity and
paralysis. Therefore, further studies to evaluate the neuroprotective effects of urolithins
and their structural analogs in animal models of AD are warranted.
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2. Experimental
2.1 Pomegranate Extract (PE).
The pomegranate extract (PE) used for the isolation studies is of the same lot number
as the PE recently reported by our group to show anti-AD effects in a transgenic animal
model [17]. The PE is a whole pomegranate fruit extract (Pomella) provided by
Verdure Sciences (Noblesville, IN) standardized to PA (ca. 30%) and EA (2.3%).

2.2 Isolation and Identification of Compounds from the PE.
Details of the isolation and identification of the compounds are provided in the
Supporting Information

2.3 Urolithins.
Urolithins (6H-dibenzo[b,d]pyran-6-one derivatives) including urolithin A (3,8dihydroxy-6H-dibenzo[b,d]pyran-6-one; UA), methyl-urolithin A (3-hydroxy-8methoxy-6H-dibenzo[b,d]pyran-6-one;
dibenzo[b,d]pyran-6one;

UB),

and

mUA),

urolithin

methyl-urolithin

B

(8-hydroxy-6H-

B

(8-methoxy-6H-

dibenzo[b,d]pyran6-one; mUB) were synthesized in our laboratory according to
previously reported methods [45]. Their structures were verified by NMR and mass
spectral analyses and they are all >98% purity.
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2.4 In Silico Computational Approach.
Using previously reported methods [33], BBB penetrability data including brain
transfer descriptors (Table 1) were obtained using prediction software developed by
ACD Laboratories (Toronto, Ontario, Canada).

2.5 Aβ1−42 Thioflavin T (ThT) Binding Assay.
Thioflavin T binding assay was used to measure human Aβ1−42 fibril formation as
reported previously [39]. Briefly, Aβ1−42 peptide was dissolved in ammonium
hydroxide, lyophilized, and redissolved in PBS buffer to obtain a final concentration of
50μM. Treatments included 10 or 100μg/mL of PE, and 10 or 100μM of PE
constituents (PA, GA, and EA), urolithins (UA, UB, mUA, and mUB), and the positive
control, resveratrol. After 10 days incubation at 37°C, 20μL of each sample was added
to 100 μL of ThT solution (10μM) and fluorescence was measured using a Spectra Max
M2 spectrometer (Molecular Devices, Sunnyvale, CA) at excitation and emission
wavelengths of 450 and 483nm, respectively. To evaluate the inhibitory effects on ThT
binding, the activity of each treatment was expressed as a percent inhibition value (%
inhibition) relative to the negative control. Percent inhibition was calculated by [(FU
of negative control − FU of treated solution)/ FU of negative control] × 100% based on
arbitrary fluorescence (FU). Statistical significance was analyzed by one-way factorial
ANOVA with Tukey−Kramer post hoc comparisons. A significance value of p < 0.05
were set to evaluate the group difference, n = 3.
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2.6 C. elegans Strains, Maintenance, and Assays.
Transgenic C. elegans strain CL4176, developed to express human amyloid β1−42 in the
muscle tissue in response to heat shock [46], were obtained from the Caenorhabditis
Genetics Center (CGC) (University of Minnesota, Minneapolis, MN). Worms were
grown and maintained at 16°C on 60mm culture plates with Nematode Growth Medium
(NGM) (1.7% agar, 0.3% NaCl, 0.25% peptone, 1mM CaCl2, 1mM MgSO4, 5mg/L
cholesterol, 2.5mM KPO4 at 16−20°C). Media was poured aseptically into culture
plates (10mL for 60mm) using a peristaltic pump and allowed to solidify for 36h. NGM
culture plates were then inoculated with 50 μL of Escherichia coli OP50 (CGC,
University of Minnesota, Minneapolis, MN) overnight cultures and incubated for 8h at
37°C. Strains of C. elegans were maintained by picking 2−3 young adult worms onto
freshly inoculated NGM plates every 4−7 days.

2.7 Age Synchronization of C. elegans.
Prior to the beginning of the experiment, C. elegans were age synchronized as
previously described [47, 48]. Briefly, 10 worms at L4 stage (F0) were transferred to
single NGM plates and incubated at 16°C until they progressed to adulthood and laid
eggs. Adults were immediately removed from the plates and the eggs were allowed to
hatch (F1) and grow to L4 at 16°C. L4 worms of the F1 generation were again
transferred to fresh NGM plates and allowed to mature into gravid adults and lay eggs
at 16°C. Adults were quickly removed from the plates and returned to a 16 °C incubator
to facilitate egg hatching. L1 worms (F2 generation) were collected from the plate by
washing with S-basal buffer (0.59% NaCl, 5% 1M KPO4, 5mg/mL cholesterol in

128

ethanol) into a sterile 15mL centrifuge tube. Worms from a minimum of five plates
were pooled into a single centrifuge tube and centrifuged at 8000rpm for 10min at
10°C. The supernatant was carefully aspirated and the worms were washed again in Sbasal buffer, centrifuged, and aspirated to leave approximately 1mL of S-basal buffer
in the centrifuge tube. The tube was gently agitated to disperse the worms and 20μL
was pipetted onto a slide and the number of worms was counted under a stereo
microscope. The concentration of the worms was adjusted to 10−15 worms by diluting
with S-complete liquid media (97.7% S-basal, 1% potassium citrate, 1% trace metals,
0.3% CaCl2, 0.3% MgSO4). A 100mg/mL suspension of E. coli OP50 was prepared by
centrifuging 100mL of an overnight E. coli OP50 culture in LB broth at 3500rpm. Spent
LB broth was aspirated and pellet was washed several times by resuspension and
centrifugation in sterile distilled water. The weight of the resultant pellet was
determined and adjusted to 100mg/mL using S-complete medium.

2.8 AD Assay and Treatments in Transgenic C. elegans.
Prior to the beginning of the experiment, C. elegans were age synchronized at 16°C
and L1 worms from the F2 generation were transferred to control or treatment plates
and allowed to mature gravid adult stage to lay eggs. For C. elegans treatment, stock
solutions (1mg/mL) of the samples were prepared as follows: PE and PA were
dissolved in a 1:1 (v/v) mixture of S-basal buffer and methanol and diluted in S-basal
buffer to a final concentration of 1mg/mL. EA, UA, UB, mUA, and mUB were
dissolved in DMSO and diluted in S-basal buffer to a final concentration of 1 mg/mL.
GA was dissolved in methanol and diluted in S-basal buffer to a final concentration of
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1mg/mL. For preparing the treatment plates, stock solutions of PE, PA, EA, GA, UA,
UB, mUA, and mUB were added directly to the NGM media to obtain a final
concentration of 10μg/mL. A test concentration of 10 μg/mL (i.e., 10ppm) was selected
for these assays since the test samples included an extract (i.e., PE) along with pure
compounds. However, for the pure compounds, the 10μg/mL concentration is
equivalent to the following μM concentrations: PA = 9.2μM; EA = 33.1μM, GA
=58.8μM, UA = 43.8μM, mUA = 41.3μM, UB = 47.2μM, and mUB = 44.2μM. Control
and treatment NGM plates were then inoculated with 25μL of Escherichia coli (E. coli)
OP50 suspension (100mg/mL) and incubated for 24h at 23°C. The OP50 used for
inoculation of treatment plates also contained the different treatments at a final
concentration of 10μg/mL. To standardize the food supply, the plates were then
incubated under UV light in a Stratagene UV Stratalinker 2400 (La Jolla, CA) at
maximum dose for 5 min to arrest growth of the E. coli OP50. Upon development of
the eggs to the L3 stage, the incubation temperature of the plates was increased from
16 to 25°C, in order to induce the expression of amyloid β1−42 [46]. Mobility scoring
was conducted beginning 20h after temperature upshift and continued in 2 h increments
until all of the worms were paralyzed. Three replicates per experiment were performed
with a minimum of 200 worms. Failure to respond to touch (prodding with a worm
pick) and absence of pharyngeal pumping were used to score paralyzed/dead worms.
Survival curves were plotted to calculate the mean, median, and maximum survival of
post heat shock treatment.
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2.9 Statistical Analyses.
Results are expressed as mean ± standard deviation. For the AD assay, the
Kaplan−Meier method was used to compare the lifespan survival curves and the
survival differences were tested for significance (p < 0.05) using the Log rank test
(Mantel Cox). Both tests used GraphPad Prism software 6.0 (GraphPad Software, Inc.,
San Diego, CA).
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Table 1. BBB Penetrability of Compounds Present in the PE and Urolithins (UA, UB,
mUA, and mUB) Using Computational Methods and Software Developed by ACD/Labs
(Toronto, Ontario, Canada)
compd

log P

1
−0.88
2
0.76
3
−1.26
4
0.56
5
0.67
6
1.82
7
1.64
8
−0.33
9
−0.07
10
0.80
11
0.60
12
−0.08
13
−0.58
14
−0.10
15
0.80
16
0.27
17
0.14
punicagalin 3.20
punicalin
0.69
ellagic acid 1.91
gallic acid 0.65
UA
2.87
UB
2.98
mUA
3.54
mUB
3.81

pKa

6.10
1.90
7.80
6.10
6.10
6.10
5.80
7.50
4.30
6.10
5.80
7.00
6.60
6.60
6.60
8.70
3.50
5.70
5.20
6.30
4.30
9.00
9.10
9.10
None

fraction unbound penetration rate penetration
sufficient
in plasma
(log PS)
extent (log BB) BBB
penetration
0.64
−8.10
−2.00
no
0.27
−8.20
−2.00
no
0.76
−5.00
−2.00
no
0.52
−6.90
−2.00
no
0.41
−6.80
−2.00
no
0.36
−7.10
−2.00
no
0.34
−7.40
−2.00
no
0.71
−5.50
−2.00
no
0.22
−6.60
−2.00
no
0.53
−6.70
−2.00
no
0.46
−8.10
−2.00
no
0.49
−4.70
−0.27
no
0.38
−5.80
−2.00
no
0.30
−5.20
−2.00
no
0.57
−5.10
−2.00
no
0.30
−3.60
−0.42
no
0.40
−4.90
−0.41
no
0.07
−8.30
−2.00
no
0.26
−8.00
−2.00
no
0.35
−3.70
−0.16
no
0.17
−4.20
−0.71
no
0.09
−1.40
0.01
yes
0.08
−1.20
0.03
yes
0.09
−1.60
0.38
yes
0.02
−1.10
−0.03
yes
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Table 2. Survival (Mean, Median, and Maximum) of (CL4176) C. elegans Worms
Treated with PE or Pure Compounds (10μg/ mL) 20h Post Aβ1‑42 Induction of
Muscular Paralysis at 25°Ca
concn (10 μg/mL)
survival (h)
mean
maximum
median

ctrl PE
29.45 28.20
29.47 31.70
29.00 28.00

PA
EA
27.80* 28.30
31.10 32.60*
28.00 28.00

GA
29.94
34.35*
30.00

a*

Note: p < 0.05 log rank test (Mantel Cox).
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UA
27.80*
29.50
28.00

UB
30.00
32.00*
30.00

mUA
29.90
33.02*
30.00

mUB
31.11*
33.33*
32.00*

Figure 1. (A) Chemical structures of punicalagin (PA) and ellagic acid (EA) and their
gut microbial metabolites, urolithins. (B) Chemical structures of compounds
identified in the pomegranate extract (PE).
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Figure 2. Inhibition on Aβ1−42 fibrillation measured by the ThT binding assay.
Treatments include 10 and 100μM of PE constituents (PA, EA, and GA), urolithins
(UA, UB, mUA, and mUB), and the positive control, resveratrol (Resv). The
inhibition level on ThT binding of each treated solution was expressed as a percent
inhibition value (% inhibition) relative to the negative control. % inhibition was
calculated based on arbitrary fluorescence (FU) using the following equation: %
inhibition = [(FU of negative control − FU of treated solution)/FU of negative
control] × 100%. Data was obtained from triplicate experiments (n = 3).
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Figure 3. Mobility curves of transgenic (CL4176) C. elegans 20 h post Aβ1−42 induction
of muscular paralysis at 25 °C. Kaplan−Meier mobility plots of C. elegans worms fed
on (A) control [NGM]; (B) PE [NGM + 10μg/mL PE; pomella extract]; (C) PA [NGM
+ 10μg/mL punicalagin]; (D) EA [NGM + 10μg/mL ellagic acid]; (E) UA [NGM +
10μg/mL urolithin A]; (F) UB [NGM + 10μg/mL urolithin B]; (G) mUA [NGM +
10μg/ mL methyl-urolithin A]; (H) mUB [NGM + 10μg/mL methyl-urolithin B]; and
(I) GA [NGM + 10μg/mL gallic acid].
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Synthesis of Urolithins
The synthesis of urolithin A was completed as the literature dictated [45] (Scheme 1).
Briefly, 2-bromo-5-methoxybenzoic acid (1, 2.00g), was brought to reflux in basic
(NaOH) water (15ml, pH 13.). Resorcinol (2, 5.00g) was added to the reaction and
reflux continued for 30 minutes. Aqueous CuSO4 (5% w/v, 1.80ml) was then added
and the solution was refluxed for an additional 10 minutes. During this addition, 8-Omethylurolithin A (3) began to lightly precipitate out as a light yellow/white solid. The
resulting slurry was extracted with ethyl acetate (3 x 25mL). The combined organic
layers were then washed with a saturated brine solution, and then dried over sodium
sulfate. The solution was filtered and solvent was removed in vacuo. The resultant
product was washed with cold methanol to remove any leftover starting materials and
afforded pure 8-O-methylurolithin A (Figure 1). 8-O-methylurolithin A (3, 0.040g) was
dissolved in 0.5ml anhydrous dichloromethane and 1M BBr3 in dichloromethane
(700uL) was added over several minutes. After 18 hours, the reaction was quenched
through dropwise addition of distilled water. The resultant slurry was extracted with
ethyl acetate (3 x 25mL). The combined organic layers were then washed with a
saturated brine solution, and then dried over sodium sulfate. The solution was filtered
and solvent was removed in vacuo to afford urolithin A (Figure 2).

Urolithin B (5) was synthesized similarly to 8-O-methylurolithin A, with slight
modifications in the starting materials (Scheme 2). Briefly, urolithin B requires the
starting material 2-bromobenzoic acid (6), instead of 2-bromo-5-methoxybenzoic acid
(1), however the reaction was carried out in the same manner. Urolithin B was isolated
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using silica gel column chromatography using an isocratic solvent system of 25:75
ethyl acetate:hexanes. Once urolithin B was synthesized and isolated (Figure 3),
successful methylation of the phenol was achieved using excess methyliodide and
lithium bicarbonate at room temperature in dimethylformamide to produce methylurolithin B (3-methoxy-6H-dibenzo[b,d]pyran-6-one) (7) (Scheme 2). The resultant
product was washed with cold methanol to remove any leftover starting materials and
afforded pure methyl-urolithin B (Figure 4).
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UFLC-MS/MS optimization
Metabolite identification using UFLC-MS/MS was measured using a Shimadzu UFLC
system (3 LC-20AD pumps, Degasser DGU-20A5R, autosampler SIL-20AC HT,
column oven CTO-20AC, Analyst v1.6.2) coupled to an ABSCIEX QTrap 4500 mass
spectrometer using an electrospray source interface. Identification and separation was
achieved on a reverse phase Phenomenex C18 column (250 × 4.6mm, 5m) operating
at 40°C. The mobile phases were water:formic acid (99.9:0.1 v/v; phase A) and
methanol:formic acid (99.9:0.1 v/v; phase B). Gradient program was as follows: 0–
20min, 50-100% B; 20–25min, 100% B; 25–27min, 100–50% B, 27– 32min, 50% B.
Using the synthesized standards, optimization of the MS/MS fragmentation of the
urolithins was possible. Urolithin A was optimized over each of the specific 5
transitions: [M+H] 229-195, 229-157, 229-139, 229-128, 229-114.9. Each of the
transitions is represented by a specific color: 195 blue, 157 red, 139 green, 128 grey,
114.9 pale blue (Figure 5).
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Uptake of Urolithin A by C. elegans
A confluent plate of wild type N2 nematodes grown in NGM/OP50 (1.7%Agar,
0.3% NaCl, 0.25% Peptone, 1mM CaCl2, 1mM MgSO4, 5mg/L cholesterol, 2.5mM
KPO4) (100L of overnight OP50 E. coli culture) were washed from the plate with two
washes of 5mL of S-Basal buffer (0.59% NaCl, 5% KPO4, 5mg/ml cholesterol) and
transferred to a 15mL centrifuge tube. Then 100L of a 50M solution of Urolithin A
(0.05% DMSO and Water) was added to the nematodes/buffer solution. The nematodes
were incubated at 20C for 4 hours. After incubation the nematodes were centrifuged
at 1200 rpm for five minutes. The supernatant was decanted and the nematodes were
washed three times with 10mL of PBS +1% BSA, 10mL of PBS + 0.01% Tween20,
and 10mL PBS. After the final wash the supernatant was decanted and the dry pellet
was stored at -80C.

1mL of 50:49.9:0.1 (MeOH:H2O:HCl, v/v) was added to the samples and stored in 80°C until completely frozen into a solid. Samples were removed from the freezer and
sonicated for 15 minutes in an ice water bath, or until the sample had melted. Three
rounds of freezing/sonication took place to ensure the rupture of the C. elegans.
Samples were centrifuged (Eppendorf Centrifuge 5804) at 5,000rpm for 5 minutes to
pellet worm body material and protein pieces. The supernatant was collected and dried
down in vacuo. 1mL of deionized water was added and the samples were sonicated for
10 minutes. The samples were eluted through a C18 SPE (Alltech, 50mg, 1mL) column.
Prior to the addition of the sample, the C18 SPE column was rinsed with 5mL of HPLC
grade methanol, followed by 2mL of deionized water.
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1mL of additional water was added to the column to elute a total of 2mL. 2mL of
tetrahydrofuran (THF) was eluted through the column. The organic layer was collected
separately and dried in vacuo. The dried organic layer was reconstituted in 200mL of
THF and 10uL was injected into the UFLC-MS/MS. Each of the mass transitions is
represented by a specific color: 195 blue, 157 red, 139 green, 128 grey, 114.9 pale blue.
Our untreated group can be found in Figure 6, while our C. elegans treated with
urolithin A can be found in figure 7.
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Polyphenol Microbial Metabolites

In addition to ellagitannin metabolism into benzopyranone derivatives, there are other
relationships between dietary polyphenols and bacterially metabolized endproducts
[1-3]. It is known that the metabolites of lignans, a common dietary polyphenol
found in flaxseed, are two smaller polyphenols enterodiol and enterolactone [2].
Additionally it was identified in the 1940s that isoflavones, found in high
concentrations in soy, require bacteria to be metabolized into equol [4]. Therefore, in
addition to the development of analytical methods for the study of ellagitannins and
urolithins, UFLC-MS/MS fragmentation to study the uptake of other polyphenol
microbial metabolites of interest, as well as other notable dietary polyphenols, has
been established (Table 1).

[1] M. Gasperotti, S. Passamonti, F. Tramer, D. Masuero, G. Guella, F. Mattivi. ACS
ChemNeuro. 2015, 16, 1341-1352.
[2] P.D. Nesbitt, Y. Lam, L.U. Am J Clin Nutr. 1999, 69, 549-555.
[3] D. Kenneth and R. Setchell. J. of Nutirition. 2000, 13, 6545-6555.
[4] T.J. Batterham, D.A. Shutt, N.K. Hart, A.W.H. Braden, H.J. Tweeddale.
Australian J. of Ag. Res. 1971, 22, 131-138
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Scheme 1. Synthesis of methyl-urolithin A (3-methoxy-8-hydroxybenzo[b,d]pyran-6one) (3) and urolithin A (3,8-dihydroxybenzo[b,d]pyran-6-one) (4) from 2-bromo-5methoxybenzoic acid (1) and resorcinol (2).
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Scheme 2. Synthesis of methyl-urolithin B (8-methoxybenzo[b,d]pyran-6-one) (5) and
urolithin B (8-hydroxybenzo[b,d]pyran-6-one) (7) from 2-bromobenzoic acid (6) and
resorcinol (2).
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Table 1: MS/MS fragmentation of other polyphenol microbial metabolites of interest,
as well as other notable dietary polyphenols. MS3 designated by (*), MS4 designated
by (+).
Polyphenol Name

Mass Transition

Secoisolariciresinol

[M+H] 363.42, 345, 295, 327*, 263*, 163*, 137+, 133*

Enterodiol

[M+H] 303.37, 285, 267*, 147+, 133+, 107+

Enterolactone

[M+H] 299.34, 281*, 263+, 133+, 107*

Daidzein

[M+H] 255.23, 237, 227, 199*, 181*, 137

Equol

[M+H] 243.3, 149, 133, 123, 107

Quercetin

[M+H] 303.24, 257, 229*, 165, 153, 137

Curcumin

[M+H] 369.39, 284, 253*, 245, 177, 145*

Desmethoxycurcumin [M+H] 339.36, 255, 223*, 177, 145*
Punicalagin

[M+H] 1085.7, 106.78, 783, 765*, 621*, 603*, 557+, 303+

Punicalin

[M+H] 783.52. 765, 603*, 557+, 303+

Ellagic Acid

[M+H] 303.2, 285, 275, 257*, 247*, 229+, 201+
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Figure 2. 1H NMR of synthesized urolithin A (3,8-dihydroxybenzo[b,d]pyran-6-one).
Data was measured in CH3OD at 500 MHz (1H) and 125 MHz (13C).
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Figure 3. 1H NMR of synthesized methyl-urolithin b (8-methoxybenzo[b,d]pyran-6one). Data was measured in CH3OD at 500 MHz (1H) and 125 MHz (13C).
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Figure 4. 1H NMR of synthesized urolithin b (8-hydroxybenzo[b,d]pyran-6-one).
Data was measured in CH3OD at 500 MHz (1H) and 125 MHz (13C).
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Figure 5. UFLC-MS/MS transitions of the fragmentation of UA standard. Each
transition is represented by a specific color: [M+H] 229-195 blue, 229-157 red, 229139 green, 229-128 grey, 229-114.9 pale blue.
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Figure 6. UFLC-MS/MS transitions of the fragmentation of untreated worms. Each
MS/MS transition of UA is represented by a specific color: [M+H] 229-195 blue, 229157 red, 229-139 green, 229-128 grey, 229-114.9 pale blue.
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Figure 7. UFLC-MS/MS transitions of the fragmentation of worms treated with UA.
Each MS/MS transition of UA is represented by a specific color: [M+H] 229-195
blue, 229-157 red, 229-139 green, 229-128 grey, 229-114.9 pale blue.
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CONCLUSIONARY REMARKS
Well known medicinal chemist and text book author, Dr. Richard Silverman, describes
medicinal chemistry in The Organic Chemistry of Drug Design and Delivery:
“Medicinal Chemistry may involve isolation of compounds from nature
or the synthesis of new molecules, investigations of the relationships
between the structure of natural and/or synthetic compounds and their
biological activates, elucidations of their interactions with receptors of
various kinds, the determination of their absorption, transport and
distributions properties, and studies of metabolic transformations.”
Dr. Silverman’s lengthy description of medicinal chemistry highlights how diverse the
studies of drug discovery, and drug development, can be during the preclinical stages.
The work provided in this dissertation highlights several key elements of Dr.
Silverman’s definition, including the isolation of compounds from nature, the synthesis
of new molecules, elucidations of the interactions between receptors and their ligands,
and studies of metabolic transformations.

The phytochemical investigation of Carex vulpinoidea (Fox Sedge) in pursuit of novel
stilbenes concluded with the identification and structural elucidation of two new
monomeric stilbenes, namely, vulpinoideols A and B. A synthetic route for naturally
isolated gallotannins, namely, maplexins F and J, previously isolated from red maple
(Acer rubrum) tree bark, was developed. Additionally, the ligand-enzyme interaction
between the gallotannins and their target enzyme, α-glucosidase, was evaluated using
biophsyical tools. Finally, a synthetic route was also developed for the ellagitannin gut156

microbial metabolites, urolithins (dibenzopyranone derivatives), along with analytical
UFLC-MS/MS methods to study the cellular and tissue uptake of the urolithins, as well
as other dietary polyphenolic metabolites of interest.

While today’s pharmaceuticals trend towards increasing the generation and
administration of larger macromolecules, straying from the traditional small molecules,
I believe that there will continue to be a demand for novel small molecule driven
research. Traditionally, the research has been motivated by a single compound driving
a single biological response, however I believe the future momumental discoveries of
small molecules and natural products will involve the complex interactions and
diversity of compounds found in botanical extracts. Even now while conclusive data
on the effectiveness, pharmacological, and toxicological data is difficult to identify,
dietary polyphenols continue to attract both media and research attention. Additionally,
we are only just beginning to scratch the surface of knowledge into the gut microbiota.
In the future lies extensive analytical and instrumental advances, which will allow us
to tease apart the complex biochemical relationships, and their metabolisms.
R.B. Silverman and M.W. Holladay. The organic chemistry of drug design and drug
delivery. Elsevier Inc, San Diego California, USA. 2014.
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